


# Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update July 13 - July 19, 2020,

Dr. Peter J. Lansberg MD, PhD

---

## ***Weekly COVID-19 Literature Update***

will keep you up-to-date with all recent PubMed publications  
categorized by relevant topics

---

## **COVID-19 publications - Week 29 2020** 901 Publications

---

### **PubMed based Covid-19 weekly literature update**

For those interested in receiving weekly updates  
click [here](#)

For questions and requests for topics to add send an e-mail  
[lansberg@gmail.com](mailto:lansberg@gmail.com)

### **Reliable on-line resources for Covid 19**

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

## **Guidelines**

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

## **Trials & Registries**

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

## **Mainstream Media**

[New York Times - Corona update](#)

[Three Coronavirus Vaccine Developers Report Promising Initial Results](#)  
[New Treatment for Covid-19 Shows Promise, but Scientists Urge Caution](#)  
[Once a Model City, Hong Kong Grapples With a New Coronavirus Wave](#)  
[During Coronavirus Lockdowns, Some Doctors Wondered: Where Are the Premies?](#)  
[What Is It That Keeps Most Little Kids From Getting Covid-19?](#)

## Washington Post - Corona update

[Halfway through the year, the pandemic is only intensifying in many states](#)  
[Trump administration](#)  
[Pushing to block new money for testing, tracing and CDC](#)  
[It's not only coronavirus cases that are rising. Now covid deaths are, too.](#)

## Guardian - Corona update

[Coronavirus world map: which countries have the most Covid-19 cases and deaths?](#)  
[What kind of face mask gives the best protection against coronavirus?](#)  
[Covid-19: what can sewage tell us?](#)  
[Trial of Covid-19 drug given via inhaler 'very promising', say scientists](#)  
[Coronavirus vaccine tracker: how close are we to a vaccine?](#)

## Key Articles

1. **SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity.** Am J Clin Pathol 2020; Phipps WS, SoRelle JA, Li QZ *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32666092>
2. **COVID-19: review and hematologic impact.** Clin Chim Acta 2020; Leticia de Oliveira Toledo S, Sousa Nogueira L, das Gracas Carvalho M *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32659224>
3. **The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.** J. Am. Med. Dir. Assoc. 2020; 21:909-914.e902De Spiegeleer A, Bronselaer A, Teo JT *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32674818>
4. **Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19.** Hypertension 2020; Qin JJ, Cheng X, Zhou F *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32673499>
5. **Absence of in-flight transmission of SARS-CoV-2 likely due to use of face masks on board.** J Travel Med 2020; Nir-Paz R, Grotto I, Strolov I *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32662832>
6. **Obesity and mortality of COVID-19. Meta-analysis.** Obes. Res. Clin. Pract. 2020; Hussain A, Mahawar K, Xia Z *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32660813>

7. **Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection.** Clin Chim Acta 2020; Hu X, Chen D, Wu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653486>
  8. **New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.** BMC Med 2020; 18:216 Hou Y, Zhao J, Martin W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664879>
  9. **Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis.** Int J Environ Res Public Health 2020; 17: Ghayda RA, Lee J, Lee JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668763>
  10. **Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.** Eur Heart J 2020; Fauvel C, Weizman O, Trimaille A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656565>
  11. **High Thrombus Burden in Patients with COVID-19 Presenting with ST-Elevation Myocardial Infarction.** J Am Coll Cardiol 2020; Choudry FA, Hamshere SM, Rathod KS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679155>
  12. **Pharmacotherapeutics Advice in Guidelines for COVID-19.** Front. Pharmacol. 2020; 11:950 Chen ZR, Zhou Y, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670066>
  13. **Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?** J Am Coll Cardiol 2020; 76:277-279 Bloch MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674791>
  14. **QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.** J. Interv. Card. Electrophysiol. 2020; B CH, Greige N, J AQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654098>
  15. **Detection of SARS-CoV-2 RNA in commercial passenger aircraft and cruise ship wastewater: a surveillance tool for assessing the presence of COVID-19 infected travelers.** J Travel Med 2020; Ahmed W, Bertsch PM, Angel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662867>
- 

## Basic Science (32 articles)

1. **Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular Mechanism.** ACS Chem Neurosci 2020; Bilinska K, Butowt R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673476>
2. **Can the Environmental Phagocyte Acanthamoeba Be a Useful Model to Study SARS-CoV-2 Pathogenicity, Infectivity, and Evasion of Cellular Immune Defenses?** ACS Chem Neurosci 2020; Siddiqui R, Khan NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662981>

3. **Single-cell RNA Expression Profiling of ACE2, The Receptor of SARS-CoV-2.** *Am J Respir Crit Care Med* 2020; Zhao Y, Zhao Z, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663409>
4. **Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.** *Antiviral Res* 2020:104873 Kim SY, Jin W, Sood A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653452>
5. **Targeting zinc metalloenzymes in COVID-19.** *Br J Pharmacol* 2020; Doboszewska U, Wlaz P, Nowak G, Mlyniec K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671829>
6. **Is 'happy hypoxia' in COVID-19 a disorder of autonomic interoception? A hypothesis.** *Clin. Auton. Res.* 2020; Gonzalez-Duarte A, Norcliffe-Kaufmann L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671502>
7. **Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill COVID-19 patients.** *Clin Infect Dis* 2020; Dupont V, Kanagaratnam L, Goury A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672790>
8. **Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans.** *Comput. Biol. Med.* 2020; 122:103849 Robson B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658736>
9. **Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.** *Computation (Basel)* 2020; 8Qiao Z, Zhang H, Ji HF, Chen Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661494>
10. **Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus-2 proteome.** *Drug Dev Res* 2020; Sadia A, Basra MAR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662099>
11. **A Molecular Docking Study Repurposes FDA Approved Iron Oxide Nanoparticles to Treat and Control COVID-19 Infection.** *Eur. J. Pharm. Sci.* 2020:105465 Abo-Zeid Y, Ismail NS, McLean GR, Hamdy NM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668312>
12. **Immune and Metabolic Signatures of COVID-19 Revealed by Transcriptomics Data Reuse.** *Front. Immunol.* 2020; 11:1636 Gardinassi LG, Souza COS, Sales-Campos H, Fonseca SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670298>
13. **MicroGMT: A Mutation Tracker for SARS-CoV-2 and Other Microbial Genome Sequences.** *Front. Microbiol.* 2020; 11:1502 Xing Y, Li X, Gao X, Dong Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670259>
14. **Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.** *Future Med. Chem.* 2020; VanPatten S, He M, Altiti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672061>
15. **The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer.** *Future Oncol* 2020; Mollica V, Rizzo A, Massari F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658591>
16. **SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.** *Inflamm Res* 2020; Oberemok VV, Laikova KV, Yurchenko KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656668>
17. **Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines.** *Int. J. Biol. Macromol.* 2020; Chen X, Han W, Wang G, Zhao X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679328>
18. **Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection.** *Int J Clin Res Trials* 2020; 5Zhyvotovska A, Yusupov D, Foronjy R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676542>
19. **COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks.** *Int J Mol Sci* 2020; 21Blaess M, Kaiser L, Sauer M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668803>
20. **Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.** *J Biomol Struct Dyn* 2020:1-13 Andrianov AM, Kornoushenko YV, Karpenko AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662333>
21. **Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches.** *J Biomol Struct Dyn* 2020:1-19 Idris MO, Yekeen AA, Alakanse OS, Durojaye OA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672528>
22. **Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL(pro)).** *J Biomol Struct Dyn* 2020:1-21 Koulgi S, Jani V, Uppuladinne M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679006>
23. **Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies.** *J Biomol Struct Dyn* 2020:1-13 Mishra SS, Ranjan S, Sharma CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666910>
24. **SARS-CoV-2 replicating in non-primate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.** *J Med Virol* 2020; Chen JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681650>
25. **SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.** *J. Struct. Biol.* 2020:107575 Griffin JWD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653646>
26. **EMMPRIN/BASIGIN as a biological modulator of oral cancer and COVID-19 interaction: Novel propositions.** *Med. Hypotheses* 2020; 143:110089 Varadarajan S, Balaji TM, Sarode SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673940>
27. **High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.** *Molecules* 2020; 25Olubiyi OO, Olagunju M, Keutmann M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668701>
28. **Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19).** *Pathog Dis* 2020; Jia Z, Song X, Shi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667665>
29. **Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein.** *Protein Sci.* 2020; Ye Q, West AMV, Silletti S, Corbett KD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654247>
30. **Computer modelling of a potential agent against SARS-Cov-2 (COVID-19) protease.** *Proteins* 2020; Lesk AM, Konagurthu AS, Allison L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662915>



31. **COVID-19 and purinergic signaling: the need for investigation.** *Purinergic Signal* 2020; Cardoso AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661586>
32. **RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.** *SLAS Discov* 2020;2472555220942123Zhu W, Chen CZ, Gorshkov K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660307>

## Biomarkers - Genetics (83 articles)

1. **Rapid Gel Card Agglutination Assays for Serological Analysis Following SARS-CoV-2 Infection in Humans.** *ACS Sens* 2020; Alves D, Curvello R, Henderson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672954>
2. **SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis.** *Am J Clin Pathol* 2020; Prilutskiy A, Kritselis M, Shevtsov A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681166>
3. **Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19.** *Am. J. Infect. Control* 2020; Boger B, Fachi MM, Vilhena RO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659413>
4. **Blood type and outcomes in patients with COVID-19.** *Ann. Hematol.* 2020; Latz CA, DeCarlo C, Boitano L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656591>
5. **The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort.** *Biomark. Med.* 2020; Ayanian S, Reyes J, Lynn L, Teufel K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677844>
6. **Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study.** *BMC Infect. Dis.* 2020; 20:519Wang D, Li R, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677918>
7. **New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.** *BMC Med* 2020; 18:216Hou Y, Zhao J, Martin W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664879>
8. **Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic.** *Br. J. Oral Maxillofac. Surg.* 2020; Herron JBT, Dennis J, Brennan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660877>
9. **Serum prealbumin deserves more significance in the early triage of COVID-19 patients.** *Clin Chem Lab Med* 2020; Guo XL, Zhang Y, Zeng YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681771>
10. **Laboratory work safety rules and guidelines during COVID-19 pandemic in Polish clinical laboratories - do our laboratories work according to a recent IFCC Taskforce Recommendations?** *Clin Chem Lab Med* 2020; Malecka M, Ogrodzinska K, Salczynska G, Ciepiela O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673282>
11. **The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19.** *Clin Chim Acta* 2020; Deng P, Ke Z, Ying B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681933>
12. **Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection.** *Clin Chim Acta* 2020; Hu X, Chen D, Wu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653486>
13. **Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill COVID-19 patients.** *Clin Infect Dis* 2020; Dupont V, Kanagaratnam L, Goury A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672790>
14. **The laboratory's role in combating COVID-19.** *Crit. Rev. Clin. Lab. Sci.* 2020:1-15Fang B, Meng QH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662342>
15. **Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection.** *Cytometry A* 2020; Gatti A, Radrizzani D, Vigano P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654350>
16. **COVID-19 associated pneumonia despite repeatedly negative PCR-analysis from oropharyngeal swabs.** *Deutsche Medizinische Wochenschrift* 2020; 145:844-849Hornuss D, Laubner K, Monasterio C *et al.*
17. **How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory.** *Diagn. Microbiol. Infect. Dis.* 2020; 98:115123Thwe PM, Ren P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673978>
18. **Higher testing coverage is associated with lower COVID-19 mortality rate: insights from Italian regions.** *Disaster Med Public Health Prep* 2020:1-11Saglietto A, Moirano G, Anselmino M, De Ferrari GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660686>
19. **Pooled Testing for Expanding COVID-19 Mass Surveillance.** *Disaster Med Public Health Prep* 2020:1-5Sunjaya AF, Sunjaya AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660684>
20. **Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?** *Elife* 2020; 9Pique-Regi R, Romero R, Tarca AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662421>
21. **Patients presenting for hospital-based screening for COVID-19: risk of disease, and healthcare access preferences.** *Emerg. Med. Australas.* 2020; Rojek A, Dutch M, Peyton D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671974>
22. **Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy?** *ESMO Open* 2020; 5Zambelli A, Tondini CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661020>
23. **Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.** *Eur Heart J* 2020; Fauvel C, Weizman O, Trimaille A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656565>
24. **False-Negative Nasopharyngeal Swab RT-PCR Assays in Typical COVID-19: Role of Ultra-low-dose Chest CT and Bronchoscopy in Diagnosis.** *Eur J Case Rep Intern Med* 2020; 7:001680Marando M, Tamburello A, Gianella P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670990>
25. **How should our testing behaviour change with time in children in current COVID-19 pandemic?** *Eur. J. Clin. Invest.* 2020:e13351Zhang Y, Lin J, Xu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681526>
26. **Variplex test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction.** *Eur J Clin Microbiol Infect Dis* 2020; Eckel F, Kusters F, Drossel B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681309>

27. **Hematological Manifestations of COVID-19: From Cytopenia to Coagulopathy.** *Eur. J. Haematol.* 2020; Agbuduwe C, Basu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663356>
28. **International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020.** *Euro Surveill* 2020; 25:Matheeußen V, Corman VM, Donoso Mantke O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672149>
29. **Direct on-the-spot detection of SARS-CoV-2 in patients.** *Exp. Biol. Med. (Maywood)* 2020:1535370220941819Ben-Assa N, Naddaf R, Gefen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668983>
30. **Forensic DNA testing during the SARS-CoV-2 pandemic.** *Forensic Sci Int Genet* 2020:102346De Ungria MCA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660901>
31. **Immune and Metabolic Signatures of COVID-19 Revealed by Transcriptomics Data Reuse.** *Front. Immunol.* 2020; 11:1636Gardinassi LG, Souza COS, Sales-Campos H, Fonseca SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670298>
32. **Human Sialome and Coronavirus Disease-2019 (COVID-19) Pandemic: An Understated Correlation?** *Front. Immunol.* 2020; 11:1480Mornioli D, Gianni ML, Consales A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655580>
33. **Re-positive Cases of Nucleic Acid Tests in Discharged Patients With COVID-19: A Follow-Up Study.** *Front Med (Lausanne)* 2020; 7:349Qiao XM, Xu XF, Zi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656223>
34. **MicroGMT: A Mutation Tracker for SARS-CoV-2 and Other Microbial Genome Sequences.** *Front. Microbiol.* 2020; 11:1502Xing Y, Li X, Gao X, Dong Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670259>
35. **Vitamin D Deficiency and Air Pollution Exacerbate COVID-19 Through Suppression of Antiviral Peptide LL37.** *Front Public Health* 2020; 8:232Crane-Godreau MA, Clem KJ, Payne P, Fiering S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671009>
36. **A Low Viral Dose in COVID-19 Patient: A Case Report.** *Front Public Health* 2020; 8:339Li Y, Hu X, Tu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671013>
37. **A one-step, one-tube real-time RT-PCR based assay with an automated analysis for detection of SARS-CoV-2.** *Heliyon* 2020; 6:e04405Dharavath B, Yadav N, Desai S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665985>
38. **Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19.** *Hypertension* 2020; Qin JJ, Cheng X, Zhou F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673499>
39. **Effects of Renin-Angiotensin Inhibition on ACE2 and TMPRSS2 Expression: Insights into COVID-19.** *Hypertension* 2020; Wu C, Ye D, Mullick AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673509>
40. **Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease.** *Immunity* 2020; Schultheiss C, Paschold L, Simnica D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668194>
41. **COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.** *Immunol. Res.* 2020; Perricone C, Bartoloni E, Bursi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681497>
42. **The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity.** *Immunol. Rev.* 2020; Ovsyannikova IG, Haralambieva IH, Crooke SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658335>
43. **The utility of chest CT and RT-PCR screening of asymptomatic patients for SARS-CoV-2 (COVID-19) prior to semi-urgent or urgent hospital procedures.** *Infect Control Hosp Epidemiol* 2020:1-11Shah A, Walkoff LA, Kuzo RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669150>
44. **Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis.** *Int J Environ Res Public Health* 2020; 17Ghayda RA, Lee J, Lee JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668763>
45. **Changes of hematological and immunological parameters in COVID-19 patients.** *Int. J. Hematol.* 2020; Yuan X, Huang W, Ye B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656638>
46. **COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?** *Int. J. Vitam. Nutr. Res.* 2020:1-2Alshahawey M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674673>
47. **High Thrombus Burden in Patients with COVID-19 Presenting with ST-Elevation Myocardial Infarction.** *J Am Coll Cardiol* 2020; Choudry FA, Hamshere SM, Rathod KS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679155>
48. **Efficacy of a Test-Retest Strategy in Residents and Health Care Personnel of a Nursing Home Facing a COVID-19 Outbreak.** *J. Am. Med. Dir. Assoc.* 2020; 21:933-936Blain H, Rolland Y, Tuailon E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674822>
49. **Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.** *J Am Soc Nephrol* 2020; Wysocki J, Lores E, Ye M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669323>
50. **Impact of COVID-19 Pandemic on Laboratory Utilization.** *J Appl Lab Med* 2020; Durant TJS, Peaper DR, Ferguson D, Schulz WL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663258>
51. **Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19.** *J. Clin. Lab. Anal.* 2020:e23467Chen X, Yan L, Fei Y, Zhang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656888>
52. **Serological chemiluminescence immunoassay for the diagnosis of SARS-CoV-2 infection.** *J. Clin. Lab. Anal.* 2020:e23466Lijia S, Lihong S, Huabin W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671890>
53. **Hemostatic Changes in Patients with COVID-19: A Meta-Analysis with Meta-Regression.** *J Clin Med* 2020; 9Di Minno MND, Calcaterra I, Lupoli R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679766>
54. **Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19.** *J. Clin. Med. Res.* 2020; 12:448-453Chan AS, Rout A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655740>
55. **Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.** *J. Clin. Med. Res.* 2020; 12:415-422Ullah W, Basyal B, Tariq S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655735>
56. **First results of a national external quality assessment scheme for the detection of SARS-CoV-2 genome sequences.** *J Clin Virol* 2020; 129:104537Gorzer I, Buchta C, Chiba P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659712>

57. **Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.** *J Clin Virol* 2020; 129:104539 Meschi S, Colavita F, Bordi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679298>
58. **Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests.** *J Clin Virol* 2020; 129:104544 Schnurra C, Reiners N, Biemann R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663788>
59. **Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection.** *J Clin Virol* 2020; 129:104529 Serrano MM, Rodriguez DN, Palop NT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659710>
60. **Evaluation of the Aptima transcription-mediated amplification assay (Hologic(R)) for detecting SARS-CoV-2 in clinical specimens.** *J Clin Virol* 2020; 129:104541 Tremeaux P, Lhomme S, Abravanel F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659713>
61. **Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience.** *J Fungi (Basel)* 2020; 6 Gangneux JP, Reizine F, Guegan H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664423>
62. **SARS-CoV-2 infection testing at delivery: a clinical and epidemiological priority.** *J Matern Fetal Neonatal Med* 2020; 1-3 Ferrazzi E, Beretta P, Bianchi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660281>
63. **Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with Coronavirus Disease 2019.** *J Med Virol* 2020; Lin W, Xie Z, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672840>
64. **Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain Barre syndrome and polyneuritis cranialis in COVID-19 patients: a case series.** *J Med Virol* 2020; Manganotti P, Bellavita G, D'Acunto L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662899>
65. **Predictive Values of Blood Urea Nitrogen/Creatinine Ratio and Other Routine Blood Parameters on Disease Severity and Survival of COVID-19 Patients.** *J Med Virol* 2020; Ok F, Erdogan O, Durmus E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662893>
66. **Coagulopathy in COVID-19: Focus on vascular thrombotic events.** *J. Mol. Cell. Cardiol.* 2020; Shi W, Lv J, Lin L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681845>
67. **Universal screening for SARS-CoV-2 before labor admission during Covid-19 pandemic in Madrid.** *J. Perinat. Med.* 2020; Herraiz I, Folguez D, Villalain C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681783>
68. **Hypofibrinolytic state and high thrombin generation may play a major role in sars-cov2 associated thrombosis.** *J Thromb Haemost* 2020; Nougier C, Benoit R, Simon M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668058>
69. **Detection of SARS-CoV-2 RNA in commercial passenger aircraft and cruise ship wastewater: a surveillance tool for assessing the presence of COVID-19 infected travelers.** *J Travel Med* 2020; Ahmed W, Bertsch PM, Angel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662867>
70. **Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay.** *J. Virol. Methods* 2020; 113925 Goldenberger D, Leuzinger K, Sogaard KK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659240>
71. **SARS-CoV-2 RT-PCR and Chest CT, two complementary approaches for COVID-19 diagnosis.** *Jpn J Radiol* 2020; Farfour E, Mellot F, Lesprit P, Vasse M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661878>
72. **Current laboratory diagnosis of coronavirus disease 2019.** *Korean J. Intern. Med.* 2020; 35:741-748 Lim J, Lee J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668512>
73. **The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.** *Life Sci* 2020; 118097 Abbasifard M, Khorramdelazad H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679148>
74. **Using Prenatal Blood Samples to Evaluate COVID-19 Rapid Serologic Tests Specificity.** *Matern Child Health J* 2020; Alger J, Cafferata ML, Alvarado T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671537>
75. **[Neutrophil to lymphocyte ratio as a prognostic marker in COVID-19].** *Medicina (B. Aires)* 2020; 80 Suppl 3:31-36 Basbus L, Lapidus MI, Martingano I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658845>
76. **Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis.** *Microb. Pathog.* 2020; 104390 Pormohammad A, Ghorbani S, Baradaran B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681968>
77. **Corona test will now be paid for all: Asymptomatic patients go to the Public Health Service.** *MMW-Fortschritte der Medizin* 2020; 162:31.
78. **COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?** *Neuroscientist* 2020; 1073858420939033 Oliviero A, de Castro F, Coperchini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659199>
79. **Hemogram data as a tool for decision-making in COVID-19 management: applications to resource scarcity scenarios.** *PeerJ* 2020; 8:e9482 Avila E, Kahmann A, Alho C, Dorn M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656001>
80. **Testing of asymptomatic individuals for fast feedback-control of COVID-19 pandemics.** *Phys. Biol.* 2020; Muller M, Derlet PM, Mudry C, Aeppli G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674088>
81. **Disconnect between community testing and hospitalization for SARS-CoV-2 (COVID-19) infection.** *Proc. (Bayl. Univ. Med. Cent.)* 2020; 33:481 McCullough PA, Arunthamakun J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675999>
82. **Asthma prevalence in patients with SARS-CoV-2 infection detected by RT-PCR not requiring hospitalization.** *Respir. Med.* 2020; 171:106084 Garcia-Pachon E, Zamora-Molina L, Soler-Sempere MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658837>
83. **[Nasopharyngeal carriage of SARS-CoV-2 among health personnel with symptoms suggestive of COVID-19 in a University Hospital in the Paris suburbs].** *Rev. Med. Interne* 2020; Greffe S, Espinasse F, Duran C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680715>

**Children (18 articles)**



1. **Clinical and Imaging Features of COVID-19 in a Neonate.** *Chest* 2020; 158:e5-e7Xiong Y, Zhang Q, Zhao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654740>
2. **Debate: COVID-19 and psychological well-being of children and adolescents in Italy.** *Child Adolesc Ment Health* 2020; Caffo E, Scandroglio F, Asta L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654361>
3. **Debate: #Together despite the distance.** *Child Adolesc Ment Health* 2020; Chrisman AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654411>
4. **COVID-19 Outbreak and Management Approach for Families with Children on Long-Term Kidney Replacement Therapy.** *Clin J Am Soc Nephrol* 2020; Zhao R, Zhou Q, Wang XW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665227>
5. **Coronavirus Disease 2019 (COVID-19)-Associated Thromboembolic Disease: A Report of Three Patients With Pulmonary Embolism.** *Cureus* 2020; 12:e8583Guccione J, Ocazionez D, Aisenberg G, Odisio E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670718>
6. **How should our testing behaviour change with time in children in current COVID-19 pandemic?** *Eur. J. Clin. Invest.* 2020:e13351Zhang Y, Lin J, Xu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681526>
7. **Pediatrician, watch out for corona-phobia.** *Eur. J. Pediatr.* 2020; Rosenberg Danziger C, Krause I, Scheuerman O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661937>
8. **Special Attention to Diet and Physical Activity in Children and Adolescents With Obesity During the Coronavirus Disease-2019 Pandemic.** *Front Pediatr* 2020; 8:407Calcaterra V, Vandoni M, Pellino VC, Cena H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676491>
9. **Children Infected With SARS-CoV-2 From Family Clusters.** *Front Pediatr* 2020; 8:386Sun D, Zhu F, Wang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656172>
10. **CUPID COVID-19: emergency department attendance by paediatric patients during COVID-19 - project protocol.** *HRB Open Res* 2020; 3:37McDonnell T, McAuliffe E, Barrett M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666040>
11. **Medical Vulnerability of Young Adults to Severe COVID-19 Illness-Data From the National Health Interview Survey.** *J. Adolesc. Health* 2020; Adams SH, Park MJ, Schaub JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674964>
12. **COVID-19: A Review for the Pediatric Neurologist.** *J. Child Neurol.* 2020:883073820939387Christy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660309>
13. **A survey and panel discussion of the effects of the COVID-19 pandemic on paediatric urological productivity, guideline adherence and provider stress.** *J. Pediatr. Urol.* 2020; O'Kelly F, Sparks S, Seideman C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680626>
14. **Children in Coronaviruses' Wonderland: What Clinicians Need to Know.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020042Lassandro G, Palladino V, Amoroso A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670520>
15. **Management of Pediatric Rheumatological Diseases During the Outbreak of COVID-19: Our Experience.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020049Sutera D, Mazza F, Pajno GB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670527>
16. **COVID-19 in a child with tuberculous airway compression.** *Pediatr Pulmonol* 2020; Goussard P, Solomons RS, Andronikou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662947>
17. **Awareness And Concerns About Novel Coronavirus Disease 2019 (COVID-19) Among Parents Of Pediatric Liver Transplant Recipients.** *Pediatr. Transplant.* 2020:e13805Menon J, Shanmugam N, Patel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663351>
18. **Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic.** *Rheumatol. Int.* 2020; Haslak F, Yildiz M, Adrovic A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661928>

## Clinical Features (32 articles)

1. **Longer incubation period of coronavirus disease 2019 (COVID-19) in older adults.** *Aging Med (Milton)* 2020; 3:102-109Kong TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661509>
2. **Clinical Characteristics and Outcomes of 74 Patients With Severe or Critical COVID-19.** *Am. J. Med. Sci.* 2020; Li J, Xu G, Yu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653160>
3. **Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study.** *BMC Infect. Dis.* 2020; 20:519Wang D, Li R, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677918>
4. **Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection.** *Cytometry A* 2020; Gatti A, Radrizzani D, Viganò P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654350>
5. **COVID-19: Variable symptoms in mild course: olfactory loss and increased resting heart rate.** *Deutsche medizinische Wochenschrift (1946)* 2020; Isenmann A, Isenmann S.
6. **Cutaneous Complications Secondary to Haemostasis Abnormalities in COVID-19 Infection.** *Eur J Case Rep Intern Med* 2020; 7:001769Lorenzo-Villalba N, Maouche Y, Syrovatková A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665938>
7. **Hematological Manifestations of COVID-19: From Cytopenia to Coagulopathy.** *Eur. J. Haematol.* 2020; Agbuduwe C, Basu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663356>
8. **Loss of smell and taste: a new marker of COVID-19? Tracking reduced sense of smell during the coronavirus pandemic using search trends.** *Expert Rev. Anti Infect. Ther.* 2020:1-6Cherry G, Rocke J, Chu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673122>
9. **Epidemiology, prognosis and clinical manifestation of cardiovascular disease in COVID-19.** *Expert Rev. Cardiovasc. Ther.* 2020; Capone V, Cuomo V, Esposito R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672482>
10. **COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.** *Immunol. Res.* 2020; Perricone C, Bartoloni E, Bursi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681497>
11. **Climatic factors influence the spread of COVID-19 in Russia.** *Int. J. Environ. Health Res.* 2020:1-16Pramanik M, Udmale P, Bisht P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672064>
12. **An Epidemiological Study on the Prevalence of the Clinical Features of SARS-CoV-2 Infection in Romanian People.** *Int J Environ Res Public Health* 2020; 17Ciucurel C, Iconaru EI.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674479>
13. **Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis.** *Int J Environ Res Public Health* 2020; 17:Ghayda RA, Lee J, Lee JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668763>
  14. **Clinical Presentation of COVID-19: Case Series and Review of the Literature.** *Int J Environ Res Public Health* 2020; 17:Macera M, De Angelis G, Sagnelli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674450>
  15. **Silent Hypoxia in Patients with SARS CoV-2 Infection before Hospital Discharge.** *Int J Infect Dis* 2020; Fuglebjerg NJU, Jensen TO, Hoyer N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663601>
  16. **Prevalence of cheilitis in Health care workers managing COVID-19 patients.** *J Am Acad Dermatol* 2020; Singh M, Bothra A, Pawar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682030>
  17. **Caution in the time of rashes and COVID-19.** *J Am Acad Dermatol* 2020; Vesely MD, Perkins SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682026>
  18. **COVID-19: review of case reports.** *J. Anesth.* 2020; Oda Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656688>
  19. **Are salivary glands the key players in spreading COVID-19 asymptomatic infection?** *J Med Virol* 2020; da Silva Pedrosa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681673>
  20. **Are chilblains a skin expression of COVID-19 microangiopathy?** *J Thromb Haemost* 2020; Baeck M, Herman A, Peeters C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657464>
  21. **Clinical and Radiological Evaluations of COVID-19 Patients with Anosmia: Preliminary Report.** *Laryngoscope* 2020; Lechien JR, Michel J, Radulesco T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678494>
  22. **Clinical presentation and management of COVID-19.** *Med. J. Aust.* 2020; Thevarajan I, Buising KL, Cowie BC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677734>
  23. **Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020048Ucciferri C, Barone M, Vecchiet J, Falasca K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670526>
  24. **Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.** *mSphere* 2020; 5Wu Y, Huang X, Sun J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669467>
  25. **Oscillations in U.S. COVID-19 Incidence and Mortality Data Reflect Diagnostic and Reporting Factors.** *mSystems* 2020; 5Bergman A, Sella Y, Agre P, Casadevall A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665331>
  26. **COVID-19 Preliminary Case Series: Characteristics of EMS Encounters with Linked Hospital Diagnoses.** *Prehosp. Emerg. Care* 2020:1-23Fernandez AR, Crowe RP, Bourn S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677858>
  27. **Delirium as the first clinical presentation of the coronavirus disease 2019 in an older adult.** *Psychogeriatrics* 2020; Soysal P, Kara O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666597>
  28. **Trends in clinical features of novel coronavirus disease (COVID-19): A systematic review and meta-analysis of studies published from December 2019 to February 2020.** *Respir Investig* 2020; Manabe T, Akatsu H, Kotani K, Kudo K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653383>
  29. **Relationship of chest CT score with clinical characteristics of 108 patients hospitalized with COVID-19 in Wuhan, China.** *Respir Res* 2020; 21:180Zhang J, Meng G, Li W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664991>
  30. **Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment.** *Rheumatol. Int.* 2020; Shah S, Danda D, Kavadihanda C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666137>
  31. **Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison).** *Vet. Pathol.* 2020:300985820943535Molenaar RJ, Vreman S, Hakze-van der Honing RW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663073>
  32. **[Extra-pulmonary clinical manifestations of novel coronavirus pneumonia].** *Zhonghua Gan Zang Bing Za Zhi* 2020; 28:528-531Li H, Hu P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660186>

## CNS (37 articles)

1. **Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular Mechanism.** *ACS Chem Neurosci* 2020; Bilinska K, Butowt R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673476>
2. **Subjective smell and taste changes during the COVID-19 pandemic: Short term recovery.** *Am. J. Otolaryngol.* 2020; 41:102639Reiter ER, Coelho DH, Kons ZA, Costanzo RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682192>
3. **Creutzfeldt-Jakob disease in a man with COVID-19: SARS-CoV-2-accelerated neurodegeneration?** *Brain Behav Immun* 2020; Young MJ, O'Hare M, Matiello M, Schmahmann JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681865>
4. **Neurological manifestations of COVID-19: a systematic review.** *Crit Care* 2020; 24:421Nepal G, Rehrig JH, Shrestha GS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660520>
5. **Atypical Neurological Manifestations of COVID-19.** *Cureus* 2020; 12:e8518Gupta I, Reddy MK, Hussain MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656033>
6. **COVID-19: Variable symptoms in mild course: olfactory loss and increased resting heart rate.** *Deutsche medizinische Wochenschrift (1946)* 2020; Isenmann A, Isenmann S.
7. **The Development of an Epilepsy Electronic Patient Portal: Facilitating both patient empowerment and remote clinician-patient interaction in a post COVID-19 world.** *Epilepsia* 2020; Power K, McCrea Z, White M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668026>
8. **Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak.** *Eur. J. Neurol.* 2020; Chiesa-Estomba CM, Lechien JR, Radulesco T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677329>
9. **Assessment of neurological manifestations in hospitalized patients with COVID-19.** *Eur. J. Neurol.* 2020; Luigetti M, Iorio R, Bentivoglio AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681611>
10. **Loss of smell and taste: a new marker of COVID-19? Tracking reduced sense of smell during the coronavirus pandemic using search trends.** *Expert Rev. Anti Infect. Ther.* 2020:1-6Cherry G, Rocke J, Chu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673122>

11. **Neurological and Musculoskeletal Features of COVID-19: A Systematic Review and Meta-Analysis.** *Front. Neurol.* 2020; 11:687Abdullahi A, Candan SA, Abba MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676052>
12. **Accelerating Telemedicine for Cerebral Palsy During the COVID-19 Pandemic and Beyond.** *Front. Neurol.* 2020; 11:746Ben-Pazi H, Beni-Adani L, Lamdan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670193>
13. **A Contemporary Review of Neurological Sequelae of COVID-19.** *Front. Neurol.* 2020; 11:640Fiani B, Covarrubias C, Desai A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655489>
14. **Coronaviruses and Central Nervous System Manifestations.** *Front. Neurol.* 2020; 11:715Khateb M, Bosak N, Muqary M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655490>
15. **Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals.** *Headache* 2020; Porta-Etessam J, Matias-Guiu JA, Gonzalez-Garcia N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666513>
16. **Coronavirus Disease-19 Pneumonia with Facial Nerve Palsy and Olfactory Disturbance.** *Intern Med* 2020; 59:1773-1775Homma Y, Watanabe M, Inoue K, Moritaka T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669517>
17. **COVID-19: A Review for the Pediatric Neurologist.** *J. Child Neurol.* 2020:883073820939387Christy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660309>
18. **Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain Barre syndrome and polyneuritis cranialis in COVID-19 patients: a case series.** *J Med Virol* 2020; Manganotti P, Bellavita G, D'Acunto L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662899>
19. **Encephalitic syndrome and anosmia in COVID-19: do these clinical presentations really reflect SARS-CoV-2 neurotropism? A theory based on the review of 25 COVID-19 cases.** *J Med Virol* 2020; Pouga L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672843>
20. **Posterior reversible encephalopathy syndrome in patients with COVID-19.** *J Neurol Sci* 2020; 416:117019Parada SC, Gao V, Gewirtz AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679347>
21. **Ageusia and anosmia, a common sign of COVID-19? A case series from four countries.** *J. Neurovirol.* 2020; Vargas-Gandica J, Winter D, Schnippe R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666422>
22. **Clinical and Radiological Evaluations of COVID-19 Patients with Anosmia: Preliminary Report.** *Laryngoscope* 2020; Lechien JR, Michel J, Radulesco T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678494>
23. **COVID-19 in multiple sclerosis: The Dutch experience.** *Mult. Scler.* 2020:1352458520942198Loonstra FC, Hoitsma E, van Kempen ZL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662742>
24. **COVID-19 in people with multiple sclerosis: A global data sharing initiative.** *Mult. Scler.* 2020:1352458520941485Peeters LM, Parciak T, Walton C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662757>
25. **Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.** *Mult Scler Relat Disord* 2020; 44:102353Viswanathan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653804>
26. **COVID-19-Associated Guillain-Barre Syndrome: The Early Pandemic Experience.** *Muscle Nerve* 2020; Caress JB, Castoro RJ, Simmons Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678460>
27. **COVID-19 in MuSK Myasthenia Gravis: A Case Report.** *Muscle Nerve* 2020; Kushlaf H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658332>
28. **Effects of Airborne Nanoparticles on the Nervous System: Amyloid Protein Aggregation, Neurodegeneration and Neurodegenerative Diseases.** *Nanomaterials (Basel)* 2020; 10von Mikecz A, Schikowski T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664217>
29. **Neurological manifestations of SARS-CoV-2 - a systemic review.** *Neurol. Neurochir. Pol.* 2020; Slyk S, Domitrz I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667047>
30. **Electroencephalogram (EEG) in COVID-19: A systematic retrospective study.** *Neurophysiol. Clin.* 2020; Petrescu AM, Taussig D, Bouilleret V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653111>
31. **Neurovascular and perfusion imaging findings in coronavirus disease 2019: Case report and literature review.** *Neuroradiol. J.* 2020:1971400920941652Soldatelli MD, Amaral LFD, Veiga VC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666873>
32. **COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?** *Neuroscientist* 2020:1073858420939033Oliviero A, de Castro F, Coperchini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659199>
33. **Olfactory Dysfunction in COVID-19 Patients: Prevalence and Prognosis for Recovering Sense of Smell.** *Otolaryngol Head Neck Surg* 2020:194599820943530D'Ascanio L, Pandolfini M, Cingolani C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662745>
34. **Olfactory Training for Postviral Olfactory Dysfunction: Systematic Review and Meta-analysis.** *Otolaryngol Head Neck Surg* 2020:194599820943550Kattar N, Do TM, Unis GD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660334>
35. **Retrospective Observational Study of Brain Magnetic Resonance Imaging Findings in Patients with Acute SARS-CoV-2 Infection and Neurological Manifestations.** *Radiology* 2020:202422Chougar L, Shor N, Weiss N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677875>
36. **Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic.** *Telemed J E Health* 2020; Miele G, Straccia G, Moccia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667839>
37. **[Novel coronavirus infection (COVID-19) and nervous system involvement: pathogenesis, clinical manifestations, organization of neurological care].** *Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova* 2020; 120:7-16Gusev EI, Martynov MY, Boyko AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678542>

## Complications (76 articles)

1. **Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis.** *Aging (Albany NY)* 2020; 12Fang X, Li S, Yu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658868>
2. **SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis.** *Am J Clin Pathol* 2020; Prilutskiy A, Kritselis M, Shevtsov A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681166>



3. **Prevalence of Comorbidities Among Individuals With COVID-19: A Rapid Review of current Literature.** *Am. J. Infect. Control* 2020; Bajgain KT, Badal S, Bajgain BB, Santana MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659414>
4. **Clinical Characteristics and Outcomes of 74 Patients With Severe or Critical COVID-19.** *Am. J. Med. Sci.* 2020; Li J, Xu G, Yu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653160>
5. **Detection of Invasive Pulmonary Aspergillosis in COVID-19 with Non-directed Bronchoalveolar Lavage.** *Am J Respir Crit Care Med* 2020; Van Biesen S, Kwa D, Bosman RJ, Juffermans NP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668167>
6. **No added value of the modified NEWS score to predict clinical deterioration in COVID-19 patients.** *Anaesth Crit Care Pain Med* 2020; Volff M, Tonon D, Bourenne J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659455>
7. **Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study.** *Ann Intensive Care* 2020; 10:95Diehl JL, Peron N, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676824>
8. **The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort.** *Biomark. Med.* 2020; Ayanian S, Reyes J, Lynn L, Teufel K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677844>
9. **Airway management lessons from case reports of negative outcomes. Comment on Br J Anaesth; 125: e168-70.** *Br J Anaesth* 2020; Heidegger T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680606>
10. **Creutzfeldt-Jakob disease in a man with COVID-19: SARS-CoV-2-accelerated neurodegeneration?** *Brain Behav Immun* 2020; Young MJ, O'Hare M, Matiello M, Schmahmann JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681865>
11. **Hospitalized COVID-19 Patients and Venous Thromboembolism: A Perfect Storm.** *Circulation* 2020; 142:129-132Spyropoulos AC, Weitz JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658609>
12. **COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620938149Miesbach W, Makris M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677459>
13. **Is 'happy hypoxia' in COVID-19 a disorder of autonomic interoception? A hypothesis.** *Clin. Auton. Res.* 2020; Gonzalez-Duarte A, Norcliffe-Kaufmann L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671502>
14. **COVID-19: review and hematologic impact.** *Clin Chim Acta* 2020; Leticia de Oliveira Toledo S, Sousa Nogueira L, das Gracas Carvalho M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659224>
15. **Lessons of the month 3: ST-elevation myocardial infarction and left ventricular thrombus formation: an arterial thrombotic complication of severe COVID-19 infection.** *Clin Med (Lond)* 2020; 20:437-439Fenton M, Siddavaram S, Sugihara C, Husain S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675154>
16. **Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.** *Clin Rheumatol* 2020; Ahmed S, Zimba O, Gasparyan AY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654082>
17. **Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome.** *Crit Care* 2020; 24:428Garcia B, Cousin N, Bourel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665007>
18. **COVID-19-associated acute cerebral venous thrombosis: clinical, CT, MRI and EEG features.** *Crit Care* 2020; 24:419Roy-Gash F, Marine M, Jean-Michel D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653019>
19. **Immune Thrombocytopenia Purpura Secondary to COVID-19.** *Cureus* 2020; 12:e9083Bennett J, Brown C, Rouse M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676257>
20. **A Predictive Model for Patient Census and Ventilator Requirements at Individual Hospitals During the Coronavirus Disease 2019 (COVID-19) Pandemic: A Preliminary Technical Report.** *Cureus* 2020; 12:e8501Epstein RH, Dexter F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656017>
21. **Coronavirus Disease 2019 (COVID-19)-Associated Thromboembolic Disease: A Report of Three Patients With Pulmonary Embolism.** *Cureus* 2020; 12:e8583Guccione J, Ocazionez D, Aisenberg G, Odisio E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670718>
22. **Disrupting the Electrical Circuit: New Onset Atrial Fibrillation in a Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** *Cureus* 2020; 12:e9082Radwan S, Schwartz O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670726>
23. **Herpes Zoster Co-Infection in an Immunocompetent Patient With COVID-19.** *Cureus* 2020; 12:e8998Saati A, Al-Husayni F, Malibari AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670724>
24. **Prevalence of COVID-19-like symptoms among people living with HIV, and using antiretroviral therapy for prevention and treatment.** *Curr HIV Res* 2020; SeyedAlinaghi S, Ghadimi M, Hajiabdolbaghi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652912>
25. **Four Patients with COVID-19 and Tuberculosis, Singapore, April-May 2020.** *Emerg Infect Dis* 2020; 26:Tham SM, Lim WY, Lee CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667283>
26. **Three Patients with COVID-19 and Pulmonary Tuberculosis, Wuhan, China, January-February 2020.** *Emerg Infect Dis* 2020; 26:Yao Z, Chen J, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667282>
27. **SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view.** *Endocrine* 2020; Spada F, Pellicori S, Zampino G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681385>
28. **Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.** *Eur Heart J* 2020; Fauvel C, Weizman O, Trimaille A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656565>
29. **Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer.** *Eur. J. Cancer* 2020; 136:99-106Angelis V, Tippu Z, Joshi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659475>
30. **COVID-19 in a Patient with Chronic Lymphocytic Leukaemia with Pseudohypoxemia.** *Eur J Case Rep Intern Med* 2020; 7:001763Alves Barbosa O, Guimaraes Andrade T, de Almeida Sousa MD, Correia JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665936>
31. **Cutaneous Complications Secondary to Haemostasis Abnormalities in COVID-19 Infection.** *Eur J Case Rep Intern Med* 2020; 7:001769Lorenzo-Villalba N, Maouche Y, Syrovatkova A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665938>



32. **Immune Thrombocytopenic Purpura in Patients with COVID-19.** *Eur J Case Rep Intern Med* 2020; 7:001751 Revuz S, Vernier N, Saadi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665935>
33. **Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol.** *Front Med (Lausanne)* 2020; 7:372 Azabou E, Bao G, Heming N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671084>
34. **COVID-19 Sepsis and Microcirculation Dysfunction.** *Front. Physiol.* 2020; 11:747 Colantuoni A, Martini R, Caprari P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676039>
35. **How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancer.** *Future Oncol* 2020; Karacin C, Bilgetekin I, F BB, Oksuzoglu OB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677462>
36. **Subacute thyroiditis in a patient infected with SARS-CoV-2: an endocrine complication linked to the COVID-19 pandemic.** *Hormones (Athens)* 2020; Ruggeri RM, Campenni A, Siracusa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676935>
37. **Acute life-threatening cardiac tamponade in a mechanically ventilated patient with COVID-19 pneumonia.** *IDCases* 2020; 21:e00898 Derveni V, Kaniaris E, Toumpanakis D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665890>
38. **COVID-19 and Plasmodium vivax malaria co-infection.** *IDCases* 2020; 21:e00879 Sardar S, Sharma R, Alyamani TYM, Aboukamar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665888>
39. **Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic.** *Int. J. Clin. Oncol.* 2020; Aznab M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654049>
40. **COVID-19, coagulopathy and venous thromboembolism: more questions than answers.** *Intern Emerg Med* 2020; Marietta M, Coluccio V, Luppi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653981>
41. **Multidisciplinary Care of Epidermolysis Bullosa during the COVID-19 Pandemic - Consensus: Recommendations by an International Panel of Experts.** *J Am Acad Dermatol* 2020; Murrell DF, Lucky AW, Salas-Alanis JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682031>
42. **Management of crash and burn patients with SARS-CoV-2 associated ARDS.** *J. Card. Surg.* 2020; Ghodsizad A, Grant AA, Mirsaeidi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663349>
43. **Life-Threatening Psoas Hematoma due to Retroperitoneal Hemorrhage in a COVID-19 Patient on Enoxaparin Treated With Arterial Embolization: A Case Report.** *J. Clin. Med. Res.* 2020; 12:458-461 Patel I, Akoluk A, Douedi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655742>
44. **SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States.** *J Int AIDS Soc* 2020; 23:e25573 Byrd KM, Beckwith CG, Garland JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657527>
45. **COVID-19: what type of cytokine storm are we dealing with?** *J Med Virol* 2020; Monneret G, Benlyamani I, Gossez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681651>
46. **Coagulopathy in COVID-19: Focus on vascular thrombotic events.** *J. Mol. Cell. Cardiol.* 2020; Shi W, Lv J, Lin L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681845>
47. **Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19.** *J. Thromb. Thrombolysis* 2020; Bemtgen X, Zotzmann V, Benk C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653986>
48. **How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report.** *J. Thromb. Thrombolysis* 2020; Zanon E, Pasca S, Campello E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676882>
49. **COVID-19 and dengue co-infection in a returning traveller.** *J Travel Med* 2020; Epelboin L, Blonde R, Nacher M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657339>
50. **Clinical characteristics in patients with SARS-CoV-2/HBV co-infection.** *J. Viral Hepat.* 2020; Chen L, Huang S, Yang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668494>
51. **Tackling the cytokine storm in COVID-19, challenges, and hopes.** *Life Sci* 2020; 118054 Abdin SM, Elgendy SM, Alyammahi SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663575>
52. **Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations.** *Liver Int* 2020; Sonzogni A, Previtali G, Seghezzi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654359>
53. **Severe infection due to the SARS-CoV-2 coronavirus: Experience of a tertiary hospital with COVID-19 patients during the 2020 pandemic.** *Med. Intensiva* 2020; Rodriguez A, Moreno G, Gomez J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654921>
54. **[Ethical guides, criteria for admission in intensive care, palliative care. Multi-society recommendations for allocation of resources during the COVID-19 pandemic].** *Medicina (B. Aires)* 2020; 80 Suppl 3:45-64 Maglio I, Valdez P, Camera L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658848>
55. **Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020046de Sanctis V, Canatan D, Corrons JLV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670524>
56. **Severe Autoimmune Hemolytic Anemia in COVID-19 Infection, Safely Treated with Steroids.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020053 Hindilerden F, Yonal-Hindilerden I, Akar E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670531>
57. **Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020044 Malek AE, Gutierrez C, Mulanovich VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670522>
58. **Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020054 Mazzitelli M, Serapide F, Tassone B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670532>
59. **Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the COVID-19 Pandemic: An Iranian Consensus.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020050 Mousavi SA, Rad S, Rostami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670528>
60. **COVID-19-Associated Guillain-Barre Syndrome: The Early Pandemic Experience.** *Muscle Nerve* 2020; Caress JB, Castoro RJ, Simmons Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678460>
61. **Risks of aerosol drug therapy in COVID-19: much ado about nothing?** *Notfall und Rettungsmedizin* 2020; Clemens J.

62. **Coronavirus Disease 2019: Associated Multiple Organ Damage.** *Open Forum Infect Dis* 2020; 7:ofaa249Collange O, Tacquard C, Delabranche X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661498>
63. **COVID-19 Airway Management Isolation Chamber.** *Otolaryngol Head Neck Surg* 2020:194599820942500Blood TC, Jr., Perkins JN, Wistermayer PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662735>
64. **Thromboinflammation in COVID-19 acute lung injury.** *Paediatr. Respir. Rev.* 2020; Mitchell WB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653469>
65. **COVID-19 in a child with tuberculous airway compression.** *Pediatr Pulmonol* 2020; Goussard P, Solomons RS, Andronikou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662947>
66. **Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19: German Respiratory Society.** *Pneumologie* 2020; 74:337-357Pfeifer M, Pfeifer M, Pfeifer M *et al.*
67. **COVID-19 in a patient with active tuberculosis: A rare case-report.** *Respir Med Case Rep* 2020; 31:101146Faqihi F, Alharthy A, Noor A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665887>
68. **Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital.** *Rev Clin Esp* 2020; Martos Perez F, Luque Del Pino J, Jimenez Garcia N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680592>
69. **Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV.** *Rev Med Virol* 2020:e2144Kadambari S, Klenerman P, Pollard AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671966>
70. **Systematic Application of Rapid Sequence Intubation With Remifentanyl During COVID-19 Pandemic.** *Semin. Cardiothorac. Vasc. Anesth.* 2020:1089253220941369Bevilacqua S, Bottari V, Galeotti I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664787>
71. **Social Support is Key to Retention in Care during Covid-19 Pandemic among Older People with HIV and Substance Use Disorders in Ukraine.** *Subst. Use Misuse* 2020:1-3Rozanova J, Shenoi S, Zaviryukha I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666857>
72. **Pulmonary embolism in hospitalised patients with COVID-19.** *Thromb Res* 2020; 195:95-99Whyte MB, Kelly PA, Gonzalez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682004>
73. **COVID-19 in solid organ transplant recipients: dynamics of disease progression and inflammatory markers in ICU and non-ICU admitted patients.** *Transpl Infect Dis* 2020:e13407Roberts MB, Izzy S, Tahir Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654303>
74. **Liver Transplant Recipients Infected with SARS-CoV-2 in the Early Postoperative Period: Lessons from a Single Center in the Epicenter of the Pandemic.** *Transpl Infect Dis* 2020:e13418Waisberg DR, Abdala E, Nacif LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667716>
75. **Gastrointestinal diseases often lead to severe COVID-19 progression.** *Z. Gastroenterol.* 2020; 58:523-524Di Lellis MA.
76. **[Research progress of the impact of COVID-19 outbreak on people living with HIV].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E074Chen FF, Tang HL, Lyu P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654428>

## Cured – Recovered (6 articles)

1. **Disappearance of antibodies to SARS-CoV-2 in a Covid-19 patient after recovery.** *Clin Microbiol Infect* 2020; Liu A, Wang W, Zhao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653658>
2. **COVID-19 pandemic and its recovery time of patients in India: A pilot study.** *Diabetes Metab Syndr* 2020; 14:1205-1211Barman MP, Rahman T, Bora K, Borgohain C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673841>
3. **Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak.** *Eur. J. Neurol.* 2020; Chiesa-Estomba CM, Lechien JR, Radulesco T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677329>
4. **Re-positive Cases of Nucleic Acid Tests in Discharged Patients With COVID-19: A Follow-Up Study.** *Front Med (Lausanne)* 2020; 7:349Qiao XM, Xu XF, Zi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656223>
5. **Silent Hypoxia in Patients with SARS CoV-2 Infection before Hospital Discharge.** *Int J Infect Dis* 2020; Fuglebjerg NJU, Jensen TO, Hoyer N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663601>
6. **Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.** *Respir Med Case Rep* 2020; 31:101115Sodani P, Mucci L, Girolimetti R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670785>

## Cardiovascular disease (83 articles)

1. **Letter to the editor: "COVID-19 does not reduce stroke-related emergencies".** *Acta Neurol. Belg.* 2020; Caproni S, Di Schino C, Costantini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681500>
2. **A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19.** *Acta Obstet Gynecol Scand* 2020; D'Souza R, Malhame I, Teshler L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678949>
3. **Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.** *BJGP Open* 2020; Dambha-Miller H, Albasri A, Hodgson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665234>
4. **Canadian Stroke Best Practice Guidance During the COVID-19 Pandemic.** *Can. J. Neurol. Sci.* 2020; 47:474-478Smith EE, Mountain A, Hill MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654680>
5. **Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.** *Cardiovasc. Drugs Ther.* 2020; Talasaz AH, Kakavand H, Van Tassell B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671601>
6. **Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemic.** *Cardiovasc Res* 2020; Morawietz H, Julius U, Bornstein SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678443>
7. **COVID-19 complicated by ST-segment elevation myocardial infarction in a 29-year-old patient.** *Catheter. Cardiovasc. Interv.* 2020; Ong E, Castro-Dominguez Y, Brennan J, Oen-Hsiao J.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672402>
8. **Hospitalized COVID-19 Patients and Venous Thromboembolism: A Perfect Storm.** *Circulation* 2020; 142:129-132 Spyropoulos AC, Weitz JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658609>
  9. **COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620938149 Miesbach W, Makris M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677459>
  10. **Testing cardiovascular autonomic function in the COVID-19 era: lessons from Bologna's Autonomic Unit.** *Clin. Auton. Res.* 2020; Guaraldi P, Barletta G, Baschieri F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661775>
  11. **The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19.** *Clin Chim Acta* 2020; Deng P, Ke Z, Ying B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681933>
  12. **SARS-CoV-2 and the cardiovascular system.** *Clin Chim Acta* 2020; Hafiane A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681935>
  13. **Lessons of the month 3: ST-elevation myocardial infarction and left ventricular thrombus formation: an arterial thrombotic complication of severe COVID-19 infection.** *Clin Med (Lond)* 2020; 20:437-439 Fenton M, Siddavaram S, Sugihara C, Husain S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675154>
  14. **Identifying very low-risk STEMI patients for early ICU discharge in the COVID-19 era.** *Clin Res Cardiol* 2020; Altisent OA, Carrillo X, Puri R, Bayes-Genis A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661674>
  15. **Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.** *Clin Rheumatol* 2020; Ahmed S, Zimba O, Gasparyan AY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654082>
  16. **Heart Transplantation in the Early Phase of the COVID-19 Pandemic: A Single-Center Case Series.** *Clin. Transplant.* 2020:e14042 Hsu JJ, Al-Saffar F, Ardehali R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654180>
  17. **Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.** *Crit Care* 2020; 24:422 Ni W, Yang X, Yang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660650>
  18. **Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study.** *Crit Care* 2020; 24:429 Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664990>
  19. **COVID-19-associated acute cerebral venous thrombosis: clinical, CT, MRI and EEG features.** *Crit Care* 2020; 24:419 Roy-Gash F, Marine M, Jean-Michel D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653019>
  20. **Immune Thrombocytopenia Purpura Secondary to COVID-19.** *Cureus* 2020; 12:e9083 Bennett J, Brown C, Rouse M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676257>
  21. **SARS-CoV-2 (COVID 19) Infection in Hypertensive Patients and in Patients With Cardiac Disease.** *Cureus* 2020; 12:e8557 Cancarevic I, Malik BH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670694>
  22. **Acute Effusive Pericarditis: A Late Complication of COVID-19.** *Cureus* 2020; 12:e9074 Fox K, Prokup JA, Butson K, Jordan K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656050>
  23. **Coronavirus Disease 2019 (COVID-19)-Associated Thromboembolic Disease: A Report of Three Patients With Pulmonary Embolism.** *Cureus* 2020; 12:e8583 Guccione J, Ocazionez D, Aisenberg G, Odisio E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670718>
  24. **Disrupting the Electrical Circuit: New Onset Atrial Fibrillation in a Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** *Cureus* 2020; 12:e9082 Radwan S, Schwartz O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670726>
  25. **Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Induced Cardiovascular Syndrome: Etiology, Outcomes, and Management.** *Cureus* 2020; 12:e8543 Turshudzhyan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670680>
  26. **COVID-19: Variable symptoms in mild course: olfactory loss and increased resting heart rate.** *Deutsche medizinische Wochenschrift (1946)* 2020; Isenmann A, Isenmann S.
  27. **Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review.** *Diabetes Metab Syndr* 2020; 14:1133-1142 Zaki N, Alashwal H, Ibrahim S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663789>
  28. **Usefulness of echocardiography to detect cardiac involvement in COVID-19 patients.** *Echocardiography* 2020; Cameli M, Pastore MC, Soliman Aboumarie H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654210>
  29. **Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool.** *Egypt Heart J* 2020; 72:41 Momtazmanesh S, Shobeiri P, Hanaei S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661796>
  30. **Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.** *ESC Heart Fail* 2020; Tschope C, Van Linthout S, Jager S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662949>
  31. **Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.** *Eur Heart J* 2020; Fauvel C, Weizman O, Trimaille A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656565>
  32. **Cutaneous Complications Secondary to Haemostasis Abnormalities in COVID-19 Infection.** *Eur J Case Rep Intern Med* 2020; 7:001769 Lorenzo-Villalba N, Maouche Y, Syrovatkova A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665938>
  33. **Transient Type 1 Brugada Pattern without Ongoing Fever during COVID-19 Pneumonia.** *Eur J Case Rep Intern Med* 2020; 7:001808 Pasqualetto MC, Corrado A, Secco E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665941>
  34. **Multisystemic Infarctions in COVID-19: Focus on the Spleen.** *Eur J Case Rep Intern Med* 2020; 7:001747 Santos Leite Pessoa M, Franco Costa Lima C, Farias Pimentel AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665933>
  35. **Unusually Rapid Development of Pulmonary Hypertension and Right Ventricular Failure after COVID-19 Pneumonia.** *Eur J Case Rep Intern Med* 2020; 7:001784 van Dongen CM, Janssen MT, van der Horst RP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665939>
  36. **Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.** *Front. Immunol.* 2020; 11:1439 Colafrancesco S, Scivo R, Barbati C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655577>



37. **Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.** *Heart Vessels* 2020; Moschini L, Loffi M, Regazzoni V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676695>
38. **Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19.** *Hypertension* 2020; Qin JJ, Cheng X, Zhou F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673499>
39. **Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.** *Hypertension* 2020;Hypertensionaha12015464Son M, Seo J, Yang S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654557>
40. **Effects of Renin-Angiotensin Inhibition on ACE2 and TMPRSS2 Expression: Insights into COVID-19.** *Hypertension* 2020; Wu C, Ye D, Mullick AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673509>
41. **Obesity, COVID-19 and immunotherapy: the complex relationship!** *Immunotherapy* 2020; Finelli C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677493>
42. **Reply to letters vide manuscript ID IPEJ-D-20-00072, and IPEJ-D-20-00073 regarding our paper "Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.** *Indian Pacing Electrophysiol J* 2020; Kapoor A, Pandurangi U, Arora V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653526>
43. **COVID-19, coagulopathy and venous thromboembolism: more questions than answers.** *Intern Emerg Med* 2020; Marietta M, Coluccio V, Luppi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653981>
44. **Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?** *J Am Coll Cardiol* 2020; 76:277-279Bloch MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674791>
45. **High Thrombus Burden in Patients with COVID-19 Presenting with ST-Elevation Myocardial Infarction.** *J Am Coll Cardiol* 2020; Choudry FA, Hamshere SM, Rathod KS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679155>
46. **Out-of-hospital Cardiac Arrest and Acute Coronary Syndrome Hospitalizations during the COVID-19 Surge.** *J Am Coll Cardiol* 2020; Mountantonakis SE, Saleh M, Coleman K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679154>
47. **The prevalence of cardiovascular comorbidities in COVID-19, SARS and MERS: pooled analysis of published data.** *J Am Heart Assoc* 2020:e016812Liu Y, Wu S, Qin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673529>
48. **The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.** *J. Am. Med. Dir. Assoc.* 2020; 21:909-914.e902De Spiegeleer A, Bronselaer A, Teo JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674818>
49. **The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies.** *J Appl Physiol (1985)* 2020; Ferrandi PJ, Alway SE, Mohamed JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673162>
50. **Cardiothoracic surgery during the Covid-19 pandemic: Perioperative care, safety, and surgical results.** *J. Card. Surg.* 2020; Casanova J, Pissarra D, Costa R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667069>
51. **Surgical management of thoracic aortic emergency with pre- and postoperative COVID-19 disease.** *J. Card. Surg.* 2020; Mori M, Geirsson A, Vallabhajosyula P, Assi R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667075>
52. **Prioritizing cardiovascular surgical care in COVID-19 pandemic: Shall we operate or defer?** *J. Card. Surg.* 2020; Patel S, Kaushik A, Sharma AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668048>
53. **Cardiac surgery in the time of the novel coronavirus: Why we should think to a new normal.** *J. Card. Surg.* 2020; Tamagnini G, Biondi R, Ricciardi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667077>
54. **Interruption of the European Association of Cardiothoracic Anaesthesiology (EACTA) Fellowship Program During the Coronavirus Disease 2019 Pandemic: Consequences and Solutions.** *J Cardiothorac Vasc Anesth* 2020; El-Tahan MR, Schreiber JU, Diprose P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665178>
55. **QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.** *J. Interv. Card. Electrophysiol.* 2020; Hsia BC, Greige N, Quiroz JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654098>
56. **A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock.** *J Korean Med Sci* 2020; 35:e258Kim HN, Lee JH, Park HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657091>
57. **Coagulopathy in COVID-19: Focus on vascular thrombotic events.** *J. Mol. Cell. Cardiol.* 2020; Shi W, Lv J, Lin L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681845>
58. **The interplay between COVID 19 and non-communicable diseases.** *J. Stroke Cerebrovasc. Dis.* 2020;105104Chaturvedi S, Gorelick P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653107>
59. **Hypofibrinolytic state and high thrombin generation may play a major role in sars-cov2 associated thrombosis.** *J Thromb Haemost* 2020; Nougier C, Benoit R, Simon M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668058>
60. **COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness.** *J. Thromb. Thrombolysis* 2020; Du F, Liu B, Zhang S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676883>
61. **Impact of the COVID-19 pandemic on hyperacute stroke treatment: experience from a comprehensive stroke centre in Singapore.** *J. Thromb. Thrombolysis* 2020; Paliwal PR, Tan BYQ, Leow AST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661758>
62. **COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature.** *J. Thromb. Thrombolysis* 2020; Tan YK, Goh C, Leow AST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661757>
63. **Fish Oil and Covid-19 Thromboses.** *J Vasc Surg Venous Lymphat Disord* 2020; Merritt RJ, Bhardwaj V, Jami MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682081>
64. **Prognostic Value of Right Ventricular Longitudinal Strain in Patients With COVID-19.** *JACC Cardiovasc. Imaging* 2020; Li Y, Li H, Zhu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654963>
65. **Consensus statement on coronary intervention during the coronavirus disease 19 pandemic: from the Korean Society of Interventional Cardiology.** *Korean J. Intern. Med.* 2020; 35:749-757Lee KY, Lee BK, Kim WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668513>
66. **Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations.** *Liver Int* 2020; Sonzogni A, Previtali G, Seghezzi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654359>



67. **Management of adult cardiac arrest in the COVID-19 era: consensus statement from the Australasian College for Emergency Medicine.** *Med. J. Aust.* 2020; Craig S, Cubitt M, Jaison A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656798>
68. **[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].** *Medicina (B. Aires)* 2020; 80 Suppl 3:65-66Vazquez FJ, Korin J, Baldessari EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658849>
69. **Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020054Mazzitelli M, Serapide F, Tassone B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670532>
70. **Kawasaki Disease as the Immune-Mediated Echo of a Viral Infection.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020039Rigante D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670517>
71. **Cardiovascular Implications of COVID-19 Infections.** *Methodist Debaquey Cardiovasc. J.* 2020; 16:146-154Thakkar AN, Tea I, Al-Mallah MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670475>
72. **COVID-19 in multiple sclerosis: The Dutch experience.** *Mult. Scler.* 2020:1352458520942198Loonstra FC, Hoitsma E, van Kempen ZL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662742>
73. **Return to sports after COVID-19: a position paper from the Dutch Sports Cardiology Section of the Netherlands Society of Cardiology.** *Neth. Heart J.* 2020; Verwoert GC, de Vries ST, Bijsterveld N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662058>
74. **A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients.** *Neurol Sci* 2020; Sangalli D, Polonia V, Colombo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656711>
75. **Thromboinflammation in COVID-19 acute lung injury.** *Paediatr. Respir. Rev.* 2020; Mitchell WB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653469>
76. **Perioperative management of COVID-19 patients undergoing cardiac surgery with cardiopulmonary bypass.** *Perfusion* 2020:267659120941341Gunaydin S, Stammers AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666887>
77. **The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.** *Pharmacol Res Perspect* 2020; 8:e00623Braga CL, Silva-Aguiar RP, Battaglini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658389>
78. **Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.** *Pharmacol. Ther.* 2020:107628Wang JJ, Edin ML, Zeldin DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653530>
79. **In the eye of the storm: the right ventricle in COVID-19.** *Pulm Circ* 2020; 10:2045894020936660Park JF, Banerjee S, Umar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655856>
80. **Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.** *Ther. Clin. Risk Manag.* 2020; 16:595-605Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669846>
81. **Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?** *Thromb Res* 2020; 195:74-76Siguret V, Voicu S, Neuwirth M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663703>
82. **Pulmonary embolism in hospitalised patients with COVID-19.** *Thromb Res* 2020; 195:95-99Whyte MB, Kelly PA, Gonzalez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682004>
83. **COVID-19: FAQs-Congenital Heart Surgery Recovery and Defining a "New Normal".** *World J Pediatr Congenit Heart Surg* 2020:2150135120934741Dearani JA, Stephens EH, Guleserian KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662334>

## Diagnosis (4 articles)

1. **Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era.** *Am. J. Med.* 2020; Massoomi MR, Anderson RD, Ahmed MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653420>
2. **Impact of COVID-19 outbreak on regional STEMI care in Germany.** *Clin Res Cardiol* 2020; Scholz KH, Lengenfelder B, Thilo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676681>
3. **SARS-CoV-2 RT-PCR and Chest CT, two complementary approaches for COVID-19 diagnosis.** *Jpn J Radiol* 2020; Farfour E, Mellot F, Lesprit P, Vasse M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661878>
4. **COVID-19 diagnostic approaches: different roads to the same destination.** *Virusdisease* 2020; 31:97-105Kumar R, Nagpal S, Kaushik S, Mendiratta S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656306>

## DM-MS-Obesity (19 articles)

1. **The Relationship between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China.** *Am. J. Med.* 2020; Shang J, Wang Q, Zhang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653423>
2. **Gestational diabetes mellitus testing in the COVID-19 pandemic: The problems with simplifying the diagnostic process.** *Aust N Z J Obstet Gynaecol* 2020; van Gemert TE, Moses RG, Pape AV, Morris GJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662072>
3. **BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank.** *Diabetes Metab Syndr* 2020; 14:1149-1151Sattar N, Ho FK, Gill JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668401>
4. **Hypoglycemia at the time of Covid-19 pandemic.** *Diabetes Metab Syndr* 2020; 14:1143-1146Shah K, Tiwaskar M, Chawla P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668399>
5. **Impact of lockdown in COVID 19 on glycemic control in patients with type 1 Diabetes Mellitus.** *Diabetes Metab Syndr* 2020; 14:1213-1216Verma A, Rajput R, Verma S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679527>
6. **Diabetes management and specific considerations for patients with diabetes during coronavirus diseases pandemic: A scoping review.** *Diabetes Metab Syndr* 2020; 14:1109-1120Wicaksana AL, Hertanti NS, Ferdiana A, Pramono RB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659694>

7. **Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review.** *Diabetes Metab Syndr* 2020; 14:1133-1142 Zaki N, Alashwal H, Ibrahim S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663789>
8. **Diabetes and Novel Coronavirus Infection: Implications for Treatment.** *Diabetes Ther.* 2020; Williams DM, Nawaz A, Evans M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661881>
9. **Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia.** *Diabetologia* 2020; Lepper PM, Bals R, Juni P, von Eynatten M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676817>
10. **Special Attention to Diet and Physical Activity in Children and Adolescents With Obesity During the Coronavirus Disease-2019 Pandemic.** *Front Pediatr* 2020; 8:407 Calcaterra V, Vandoni M, Pellino VC, Cena H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676491>
11. **Pre-gestational diabetes during the COVID-19 pandemic in Bergamo, Italy.** *Int J Gynaecol Obstet* 2020; Dodesini AR, Galliani S, Ciriello E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657430>
12. **Diabetes Mellitus Association with Coronavirus Disease 2019 (COVID-19) Severity and Mortality: A Pooled Analysis.** *J. Diabetes* 2020; Aggarwal G, Lippi G, Lavie CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677321>
13. **Factors Leading to High Morbidity and Mortality of COVID-19 in Patients with Type 2 Diabetes.** *J. Diabetes* 2020; Rajpal A, Rahimi L, Ismail-Beigi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671936>
14. **The role of visceral adiposity in the severity of COVID-19: highlights from a unicenter cross-sectional pilot study in Germany.** *Metabolism* 2020:154317 Petersen A, Bressen K, Albrecht J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673651>
15. **Commentary: COVID-19 and Obesity: Exploring Biologic Vulnerabilities, Structural Disparities, and Weight Stigma.** *Metabolism* 2020:154316 Townsend MJ, Kyle TK, Stanford FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673650>
16. **Obesity and COVID-19: The Two Sides of the Coin.** *Obes Facts* 2020:1-9 Dicker D, Bettini S, Farpour-Lambert N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659766>
17. **Obesity and mortality of COVID-19. Meta-analysis.** *Obes. Res. Clin. Pract.* 2020; Hussain A, Mahawar K, Xia Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660813>
18. **Awareness regarding COVID-19 and problems being faced by young adults with type 1 diabetes mellitus amid nationwide lockdown in India: A qualitative interview study.** *Prim. Care Diabetes* 2020; Pal R, Yadav U, Verma A, Bhadada SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660907>
19. **COVID-19 and diabetes: What does the clinician need to know?** *Prim. Care Diabetes* 2020; Papadokostaki E, Tentolouris N, Liberopoulos E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654982>

## Education and training and science (43 articles)

1. **COVID-19 and the Radiology Match: A Residency Program's Survival Guide to the Virtual Interview Season.** *Acad Radiol* 2020; Nguyen JK, Shah N, Heitkamp DE, Gupta Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660754>
2. **Why Should SARS-CoV-2 Post-Pandemic Recovery Funding Be Used to Foster a Physician-Scientist Program?** *Acta Med Port* 2020; Barbosa-Breda J, Leal I, Sousa DC, Soares CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669183>
3. **How a Psychopharmacology Clinical Trial Site in the Seattle Area Managed Clinical Trials and Patient Care During the COVID-19 Pandemic.** *Am J Geriatr Psychiatry* 2020; Schilling S, Mohanarajah S, Mengstu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680760>
4. **Facilitating Wellbeing in a Turbulent Time.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8154 Brazeau GA, Frenzel JE, Prescott WA, Jr. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665725>
5. **Challenges and Lessons Amid the COVID-19 Pandemic at One College of Pharmacy.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8157 Draugalis JR, Johnson EJ, Urice DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665728>
6. **Assuring Quality in Pharmacy Education During a Time of Crisis.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8135 Engle JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665719>
7. **A Paradigm Shift in US Experiential Pharmacy Education Accelerated by the COVID-19 Pandemic.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8149 Fuller KA, Heldenbrand SD, Smith MD, Malcom DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665722>
8. **Fulfilling the Tripartite Mission During a Pandemic.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8156 Medina MS, Melchert RB, Stowe CD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665727>
9. **Maintaining Core Values in Postgraduate Programs During the COVID-19 Pandemic.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8158 Persky AM, Fuller KA, Jarstfer M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665729>
10. **Improving and Restoring the Well-being and Resilience of Pharmacy Students during a Pandemic.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8144 Schlesselman LS, Cain J, DiVall M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665720>
11. **Reinventing How Pharmacy Educators Connect as a Community.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8151 Sorensen TD, Lin A, Allen DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665724>
12. **The Impact of COVID-19 Through the Eyes of a Fourth-Year Pharmacy Student.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8146 Stone JK, Pate AN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665721>
13. **Perceived stress and anxiety during COVID-19 among psychiatry trainees.** *Asian J Psychiatr* 2020; 54:102282 Nanjundaswamy MH, Pathak H, Chaturvedi SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679530>
14. **Comparing the preventive behavior of medical students and physicians in the era of COVID-19: Novel medical problems demand novel curricular interventions.** *Biochem Mol Biol Educ* 2020; Haque A, Mumtaz S, Khattak O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682354>
15. **Moving the human biology program from face-to-face to online delivery mode in the time of COVID-19.** *Biochem Mol Biol Educ* 2020; Papanephytous C, Stavride P, Nicolaou SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681803>
16. **Lessons from the unexpected adoption of online teaching for an undergraduate genetics course with lab classes.** *Biochem Mol Biol Educ* 2020; Zhou C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663901>

17. **The impact of the global COVID-19 pandemic on the conduct of clinical trials. Return to normalcy by considering the practical impact of a structured ethical analysis.** *Br. J. Clin. Pharmacol.* 2020; Vissers M, Cohen AF, van Gerven JMA, Groeneveld GJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668047>
18. **Indian Publications on SARS-CoV-2: A bibliometric study of WHO COVID-19 database.** *Diabetes Metab Syndr* 2020; 14:1171-1178N VR, Patil SB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673837>
19. **Data mining and analysis of scientific research data records on Covid-19 mortality, immunity, and vaccine development - In the first wave of the Covid-19 pandemic.** *Diabetes Metab Syndr* 2020; 14:1121-1132Radanliev P, De Roure D, Walton R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659695>
20. **Accelerated importance of eHealth literacy in the COVID-19 outbreak and beyond.** *Eur. J. Cardiovasc. Nurs.* 2020;1474515120941307Brors G, Norman CD, Norekval TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667217>
21. **The impact of COVID-19 on dental education in North America-Where do we go next?** *Eur. J. Dent. Educ.* 2020; Wu DT, Wu KY, Nguyen TT, Tran SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654328>
22. **Published evidence on COVID-19 in top-ranked journals: A descriptive study.** *Eur J Intern Med* 2020; Pericas JM, Arenas A, Torrallardona-Murphy O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665174>
23. **[How to adapt qualitative research to confinement contexts].** *Gac. Sanit.* 2020; Hernan-Garcia M, Lineros-Gonzalez C, Ruiz-Azarola A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680659>
24. **Clinical trials in the pandemic age: What is fit for purpose?** *Gates Open Res* 2020; 4:58Hartman D, Heaton P, Cammack N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656501>
25. **How Medical Studies in Poland Prepare Future Healthcare Managers for Crises and Disasters: Results of a Pilot Study.** *Healthcare (Basel)* 2020; 8Miształ-Okonska P, Goniewicz K, Hertelendy AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659897>
26. **Social Distancing among Medical Students during the 2019 Coronavirus Disease Pandemic in China: Disease Awareness, Anxiety Disorder, Depression, and Behavioral Activities.** *Int J Environ Res Public Health* 2020; 17Xiao H, Shu W, Li M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674285>
27. **How COVID-19 has pushed us into a medical education revolution.** *Intern. Med. J.* 2020; Torda A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666691>
28. **Optimizing Education for Dermatology Residents During the COVID-19 Pandemic.** *J Am Acad Dermatol* 2020; Patel P, Guzman AK, McLellan B, Blasiak R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682029>
29. **Interruption of the European Association of Cardiothoracic Anaesthesiology (EACTA) Fellowship Program During the Coronavirus Disease 2019 Pandemic: Consequences and Solutions.** *J Cardiothorac Vasc Anesth* 2020; El-Tahan MR, Schreiber JU, Diprose P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665178>
30. **Achieving Effective Informed Oversight by DMCs in COVID Clinical Trials.** *J. Clin. Epidemiol.* 2020; DeMets DL, Fleming TR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659363>
31. **Call of interprofessional duty: an ethnographically informed discussion on preparing students to be digitally resilient.** *J Interprof Care* 2020;1-6Bluteau JM, Bluteau PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674649>
32. **Online interprofessional education during and post the COVID-19 pandemic: a commentary.** *J Interprof Care* 2020;1-4Khalili H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674721>
33. **COVID 19 and manual therapy: international lessons and perspectives on current and future clinical practice and education.** *J. Man. Manip. Ther.* 2020; 28:134-145MacDonald CW, Lonnemann E, Petersen SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666912>
34. **Creation of an Interactive Virtual Surgical Rotation for Undergraduate Medical Education During the COVID-19 Pandemic.** *J Surg Educ* 2020; Chao TN, Frost AS, Brody RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654999>
35. **The wave of "opinion articles" in the coverage of COVID-19 in surgical literature.** *Langenbecks Arch. Surg.* 2020; Slim K, Mattevi C, Badon F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676739>
36. **The impact of the COVID-19 pandemic on medical education.** *Med. J. Aust.* 2020; Torda AJ, Velan G, Perkovic V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681562>
37. **Letter to the editor - Participation of medical students from Latin America in the COVID-19 pandemic.** *Medwave* 2020; 20:e7968Ponce-Torres C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678808>
38. **Nurse Educators as Agents of Change in the SARS-CoV-2 Pandemic.** *Nurs. Womens Health* 2020; Klar RT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659222>
39. **COVID-19 and telehealth, education, and research adaptations.** *Paediatr. Respir. Rev.* 2020; Wijesooriya NR, Mishra V, Brand PLP, Rubin BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653468>
40. **Clinical trials during the COVID-19 pandemic: Challenges of putting scientific and ethical principles into practice.** *Perspect. Clin. Res.* 2020; 11:59-63Bhatt A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670829>
41. **The knowledge level and perceptions towards COVID-19 among Turkish final year medical students.** *Postgrad. Med.* 2020; Caliskan F, Midik O, Baykan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657235>
42. **The role of surgeons during the COVID-19 pandemic: impact on training and lessons learned from a surgical resident's perspective.** *Surg. Endosc.* 2020; Wady H, Restle D, Park J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666253>
43. **[Research progress of the impact of COVID-19 outbreak on people living with HIV].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E074Chen FF, Tang HL, Lyu P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654428>

## Elderly (19 articles)

1. **Comparing associations between frailty and mortality in hospitalised older adults with or without COVID-19 infection: a retrospective observational study using electronic health records.** *Age Ageing* 2020; Owen RK, Conroy SP, Taub N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678866>
2. **Improving the care of older patients during the COVID-19 pandemic.** *Ageing Clin. Exp. Res.* 2020; Bianchetti A, Bellelli G, Guerini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654005>



3. **Longer incubation period of coronavirus disease 2019 (COVID-19) in older adults.** *Aging Med (Milton)* 2020; 3:102-109Kong TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661509>
4. **Age, source, and future risk of COVID-19 infections in two settings of Hong Kong and Singapore.** *BMC Res. Notes* 2020; 13:336Zhu S, Tao J, Gao H, He D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660556>
5. **Reorganisation of primary care for older adults during COVID-19: a cross-sectional database study in the UK.** *Br. J. Gen. Pract.* 2020; Joy M, McGagh D, Jones N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661009>
6. **Does the Coronavirus (COVID-19) Pandemic Call for a New Model of Older People Care?** *Front Public Health* 2020; 8:311Palombi L, Liotta G, Orlando S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656176>
7. **Staying afloat in the COVID-19 storm: GERIATrics Fellows Learning Online And Together (GERI-A-FLOAT).** *J Am Geriatr Soc* 2020; Duggan MC, Goroncy A, Christmas C, Chippendale R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674219>
8. **The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects.** *J. Am. Med. Dir. Assoc.* 2020; 21:915-918Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674819>
9. **Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study.** *J. Am. Med. Dir. Assoc.* 2020; 21:928-932.e921De Smet R, Mellaerts B, Vandewinckele H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674821>
10. **The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.** *J. Am. Med. Dir. Assoc.* 2020; 21:909-914.e902De Spiegeleer A, Bronselaer A, Teo JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674818>
11. **Is There a Link between Nursing Home Reported Quality and COVID-19 Cases? Evidence from California Skilled Nursing Facilities.** *J. Am. Med. Dir. Assoc.* 2020; 21:905-908He M, Li Y, Fang F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674817>
12. **The Geriatrician: The Frontline Specialist in the Treatment of COVID-19 Patients.** *J. Am. Med. Dir. Assoc.* 2020; 21:937-938Landi F, Barillaro C, Bellieni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674823>
13. **Home-Based Primary Care Led-Outbreak Mitigation in Assisted Living Facilities in the First 100 Days of Coronavirus Disease 2019.** *J. Am. Med. Dir. Assoc.* 2020; 21:951-953Mills WR, Buccola JM, Sender S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674826>
14. **Reducing Social Isolation of Seniors during COVID-19 through Medical Student Telephone Contact.** *J. Am. Med. Dir. Assoc.* 2020; 21:948-950Office EE, Rodenstein MS, Merchant TS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674825>
15. **Allowing Visitors Back in the Nursing Home During the COVID-19 Crisis: A Dutch National Study Into First Experiences and Impact on Well-Being.** *J. Am. Med. Dir. Assoc.* 2020; 21:900-904Verbeek H, Gerritsen DL, Backhaus R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674816>
16. **A Double Burden of Exclusion? Digital and Social Exclusion of Older Adults in Times of COVID-19.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Seifert A, Cotten SR, Xie B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672332>
17. **Aging and Therapy-Related Hypogammaglobulinemia causing Pneumonia: An Overlooked Curable Entity in the Chaotic COVID-19 Pandemic.** *J Med Virol* 2020; Zaidi SZA, Zaidi FZ, AlShehry N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681654>
18. **Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV.** *Rev Med Virol* 2020:e2144Kadambari S, Klenerman P, Pollard AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671966>
19. **Social Support is Key to Retention in Care during Covid-19 Pandemic among Older People with HIV and Substance Use Disorders in Ukraine.** *Subst. Use Misuse* 2020:1-3Rozanova J, Shenoi S, Zaviryukha I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666857>

## **Epidemiology 83 articles)**

1. **Avoiding a Second Wave of Medical Errors: The Importance of Human Factors in the Context of a Pandemic.** *Aesthetic Plast. Surg.* 2020; Tejos R, Navia A, Cuadra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671446>
2. **Expert consensus on protocol of rehabilitation for COVID-19 patients using framework and approaches of WHO International Family Classifications.** *Aging Med (Milton)* 2020; 3:82-94Zeng B, Chen D, Qiu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666026>
3. **Discussing Goals of Care in a Pandemic: Precedent for an Unprecedented Situation.** *Am. J. Hosp. Palliat. Care* 2020:1049909120941881Lewis A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662339>
4. **Epidemiological characteristics of the COVID-19 outbreak in a secondary hospital in Spain.** *Am. J. Infect. Control* 2020; Giesen C, Diez-Izquierdo L, Saa-Requejo CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663494>
5. **COVID-19 Outbreak in an Urban Hemodialysis Unit.** *Am J Kidney Dis* 2020; Yau K, Muller MP, Lin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681983>
6. **Social Distancing and Outdoor Physical Activity During the COVID-19 Outbreak in South Korea: Implications for Physical Distancing Strategies.** *Asia Pac. J. Public Health* 2020:1010539520940929Park S, Kim B, Lee J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667221>
7. **Early epidemiological assessment of the transmission potential and virulence of coronavirus disease 2019 (COVID-19) in Wuhan City, China, January-February, 2020.** *BMC Med* 2020; 18:217Mizumoto K, Kagaya K, Chowell G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664866>
8. **Age, source, and future risk of COVID-19 infections in two settings of Hong Kong and Singapore.** *BMC Res. Notes* 2020; 13:336Zhu S, Tao J, Gao H, He D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660556>
9. **Modelling scenarios of the epidemic of COVID-19 in Canada.** *Can. Commun. Dis. Rep.* 2020; 46:198-204Ogden NH, Fazil A, Arino J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673384>
10. **Managing COVID-19 outbreak in Nigeria: matters arising.** *Clin Chem Lab Med* 2020; Onyeaghala AA, Olajide I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681772>



11. **Response System for and Epidemiological Features of COVID-19 in Gyeongsangnam-do Province in South Korea.** Clin Infect Dis 2020; Wi YM, Lim SJ, Kim SH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672789>
12. **Experience of a novel community testing programme for COVID-19 in London: Lessons learnt.** Clin Med (Lond) 2020; Wallis G, Siracusa F, Blank M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680837>
13. **COVID-19, Australia: Epidemiology Report 20 (Fortnightly reporting period ending 5 July 2020).** Commun Dis Intell (2018) 2020; 44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664828>
14. **COVID-19 Trends and Forecast in the Eastern Mediterranean Region With a Particular Focus on Pakistan.** Cureus 2020; 12:e8582Dil S, Dil N, Maken ZH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670717>
15. **Seroprevalence and SARS-CoV-2 testing in healthcare occupations.** Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2020; Ziemssen F, Bayyoud T, Bartz-Schmidt KU *et al*.
16. **Lessons from the Ebola epidemics and their applications for COVID-19 pandemic response in sub-Saharan Africa.** Dev World Bioeth 2020; Afolabi MO, Folayan MO, Munung NS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654261>
17. **COVID-19 - 6 million cases worldwide and an overview of the diagnosis in Brazil: a tragedy to be announced.** Diagn. Microbiol. Infect. Dis. 2020; 98:115113Marson FAL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682217>
18. **Clinical and Ethical Considerations in Allocation of Ventilators in an Influenza Pandemic or Other Public Health Disaster: A Comparison of the 2007 and 2015 New York State Ventilator Allocation Guidelines.** Disaster Med Public Health Prep 2020:1-27Han SA, Koch VG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660660>
19. **Lifting of social distancing measures: Perspectives from Vietnam.** Disaster Med Public Health Prep 2020:1-8Nguyen THD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660690>
20. **COVID-19 Contact tracing solutions for mass gatherings.** Disaster Med Public Health Prep 2020:1-16Ryan BJ, Coppola D, Williams J, Swienton R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660677>
21. **Higher testing coverage is associated with lower COVID-19 mortality rate: insights from Italian regions.** Disaster Med Public Health Prep 2020:1-11Saglietto A, Moirano G, Anselmino M, De Ferrari GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660686>
22. **Pooled Testing for Expanding COVID-19 Mass Surveillance.** Disaster Med Public Health Prep 2020:1-5Sunjaya AF, Sunjaya AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660684>
23. **Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020.** Emerg Infect Dis 2020; 26Park YJ, Choe YJ, Park O *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673193>
24. **Patients presenting for hospital-based screening for COVID-19: risk of disease, and healthcare access preferences.** Emerg. Med. Australas. 2020; Rojek A, Dutch M, Peyton D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671974>
25. **First data analysis about possible COVID-19 virus airborne diffusion due to air particulate matter (PM): The case of Lombardy (Italy).** Environ. Res. 2020; 186:109639Bontempi E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668559>
26. **Estimating the number of Korean workers at high risk of COVID-19 infection.** Epidemiol Health 2020:e2020051Lee J, Kim M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660216>
27. **Time variant reproductive number of COVID-19 in Seoul, Korea.** Epidemiol Health 2020:e2020047Moon SG, Kim YK, Son WS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660220>
28. **Long-term strategies to control COVID-19 in low and middle-income countries: an options overview of community-based, non-pharmacological interventions.** Eur. J. Epidemiol. 2020; Chowdhury R, Luhar S, Khan N *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656618>
29. **Forecasting efforts from prior epidemics and COVID-19 predictions.** Eur. J. Epidemiol. 2020; Nadella P, Swaminathan A, Subramanian SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676971>
30. **Epidemiology, prognosis and clinical manifestation of cardiovascular disease in COVID-19.** Expert Rev. Cardiovasc. Ther. 2020; Capone V, Cuomo V, Esposito R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672482>
31. **COVID-19 Pandemic: Applying a Multi-Systemic Lens.** Fam. Process 2020; Rolland JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677711>
32. **Children Infected With SARS-CoV-2 From Family Clusters.** Front Pediatr 2020; 8:386Sun D, Zhu F, Wang C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656172>
33. **The Coronavirus Disease (COVID-19) Challenge in Mexico: A Critical and Forced Reflection as Individuals and Society.** Front Public Health 2020; 8:337Caldera-Villalobos C, Garza-Veloz I, Martinez-Avila N *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671012>
34. **[Predictive models of the COVID-19 epidemic in Spain with Gompertz curves].** Gac. Sanit. 2020; Sanchez-Villegas P, Daponte Codina A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680658>
35. **Population Genetics of SARS-CoV-2: Disentangling Effects of Sampling Bias and Infection Clusters.** Genomics Proteomics Bioinformatics 2020; Liu Q, Zhao S, Shi CM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663617>
36. **Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary.** Geroscience 2020; Merkely B, Szabo AJ, Kosztin A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677025>
37. **Governing COVID-19 without government in Brazil: Ignorance, neoliberal authoritarianism, and the collapse of public health leadership.** Glob Public Health 2020:1-21Ortega F, Orsini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663117>
38. **Misinformation and de-contextualization: international media reporting on Sweden and COVID-19.** Global Health 2020; 16:62Irwin RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660503>
39. **The COVID-19 Shadow Pandemic: Meeting Social Needs For A City In Lockdown.** Health Aff (Millwood) 2020:101377hlthaff202000928Clapp J, Calvo-Friedman A, Cameron S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673101>
40. **Using Information Technology To Improve COVID-19 Care At New York City Health + Hospitals.** Health Aff (Millwood) 2020:101377hlthaff202000930Salway RJ, Silvestri D, Wei E, Bouton M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673131>
41. **COVID-19 And Racial/Ethnic Disparities In Health Risk, Employment, And Household Composition.** Health Aff (Millwood) 2020:101377hlthaff202000897Selden TM, Berdahl TA.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663045>
42. **Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response.** *Health Res. Policy Syst.* 2020; 18:80Kringos D, Carinci F, Barbazza E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664985>
  43. **Correlation between the Spread of COVID-19 and the Interest in Personal Protective Measures in Poland and Portugal.** *Healthcare (Basel)* 2020; 8Strzelecki A, Azevedo A, Albuquerque A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659922>
  44. **Mathematical modeling and the transmission dynamics in predicting the Covid-19 - What next in combating the pandemic.** *Infect Dis Model* 2020; 5:366-374Anirudh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666005>
  45. **Estimation of exponential growth rate and basic reproduction number of the coronavirus disease 2019 (COVID-19) in Africa.** *Infect Dis Poverty* 2020; 9:96Musa SS, Zhao S, Wang MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678037>
  46. **Personalizing symptom monitoring and contact tracing efforts through a COVID-19 web-app.** *Infect Dis Poverty* 2020; 9:93Yap KY, Xie Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660568>
  47. **An Epidemiological Study on the Prevalence of the Clinical Features of SARS-CoV-2 Infection in Romanian People.** *Int J Environ Res Public Health* 2020; 17Ciucurel C, Iconaru EI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674479>
  48. **Modeling Spatiotemporal Pattern of Depressive Symptoms Caused by COVID-19 Using Social Media Data Mining.** *Int J Environ Res Public Health* 2020; 17Li D, Chaudhary H, Zhang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664388>
  49. **Modeling the Novel Coronavirus (SARS-CoV-2) Outbreak in Sicily, Italy.** *Int J Environ Res Public Health* 2020; 17Maugeri A, Barchitta M, Battiato S, Agodi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660125>
  50. **Health Surveillance and Response to SARS-CoV-2 Mass Testing in Health Workers of a Large Italian Hospital in Verona, Veneto.** *Int J Environ Res Public Health* 2020; 17Porru S, Carta A, Monaco MGL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679773>
  51. **COVID-19 in Yemen: a crisis within crises.** *Int J Equity Health* 2020; 19:120Mousavi SM, Anjomshoa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32652995>
  52. **"A community system": A critical foundation for the epidemic prevention and control of SARS-CoV-2.** *Int. J. Health Plann. Manage.* 2020; Zhang X, Yang S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677114>
  53. **How to Minimize the Impact of Pandemic Events: Lessons From the COVID-19 Crisis.** *Int J Health Policy Manag* 2020; Bigiani L, Bigiani S, Bigiani A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654431>
  54. **Does "Flattening the Curve" Affect Critical Care Services Delivery for COVID-19? A Global Health Perspective.** *Int J Health Policy Manag* 2020; Gilardino RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654434>
  55. **Social isolation due to the COVID-19 pandemic has led to worse outcomes in females with inflammatory arthritis.** *Ir. J. Med. Sci.* 2020; Maguire S, O'Shea F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656691>
  56. **Reducing Social Isolation of Seniors during COVID-19 through Medical Student Telephone Contact.** *J. Am. Med. Dir. Assoc.* 2020; 21:948-950Office EE, Rodenstein MS, Merchant TS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674825>
  57. **Cruise Ships, Nursing Homes, and Prisons as COVID-19 Epicenters: A "Wicked Problem" With Breakthrough Solutions?** *J. Am. Med. Dir. Assoc.* 2020; 21:958-961Sloane PD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674828>
  58. **Analysis of Covid-19 and non-Covid-19 viruses, including influenza viruses, to determine the influence of intensive preventive measures in Japan.** *J Clin Virol* 2020; 129:104543Hirotsu Y, Maejima M, Shibusawa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663787>
  59. **Community-Based Assessment of Knowledge, Attitude, Practices and Risk Factors Regarding COVID-19 Among Pakistanis Residents During a Recent Outbreak: A Cross-Sectional Survey.** *J. Community Health* 2020; Afzal MS, Khan A, Qureshi UUR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661860>
  60. **COVID-19 Pandemic: An Insult Over Injury for Lebanon.** *J. Community Health* 2020; Bizri AR, Khachfe HH, Fares MY, Musharrafieh U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661861>
  61. **Rules and guidelines on distancing in daily life for the control of COVID-19 in Korea 3rd version announced on July 3, 2020.** *J Educ Eval Health Prof* 2020; 17:20. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663925>
  62. **Restricting rural-urban connect to combat infectious disease epidemic as India fights COVID-19.** *J Family Med Prim Care* 2020; 9:1792-1794Mishra S, Mohapatra A, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670918>
  63. **Does temperature and humidity influence the spread of Covid-19?: A preliminary report.** *J Family Med Prim Care* 2020; 9:1811-1814Raina SK, Kumar R, Bhota S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670923>
  64. **Detection of SARS-CoV-2 RNA in commercial passenger aircraft and cruise ship wastewater: a surveillance tool for assessing the presence of COVID-19 infected travelers.** *J Travel Med* 2020; Ahmed W, Bertsch PM, Angel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662867>
  65. **Absence of in-flight transmission of SARS-CoV-2 likely due to use of face masks on board.** *J Travel Med* 2020; Nir-Paz R, Grotto I, Strolov I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662832>
  66. **Corona test will now be paid for all: Asymptomatic patients go to the Public Health Service.** *MMW-Fortschritte der Medizin* 2020; 162:31.
  67. **COVID-19 Pandemic and Africa: From the Situation in Zimbabwe to a Case for Precision Herbal Medicine.** *OMICS* 2020; Dandara C, Dzobo K, Chirikure S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654634>
  68. **Modelling insights into the COVID-19 pandemic.** *Paediatr. Respir. Rev.* 2020; Meehan MT, Rojas DP, Adekunle AI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680824>
  69. **Testing of asymptomatic individuals for fast feedback-control of COVID-19 pandemics.** *Phys. Biol.* 2020; Muller M, Derlet PM, Mudry C, Aepli G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674088>
  70. **Disconnect between community testing and hospitalization for SARS-CoV-2 (COVID-19) infection.** *Proc. (Bayl. Univ. Med. Cent.)* 2020; 33:481McCullough PA, Arunthamkun J.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675999>
71. **Forced social isolation due to COVID-19 and consequent mental health problems: lessons from hikikomori.** *Psychiatry Clin. Neurosci.* 2020; Kato TA, Sartorius N, Shinfuku N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654336>
  72. **An approximation-based approach for periodic estimation of effective reproduction number: a tool for decision-making in the context of coronavirus disease 2019 (COVID-19) outbreak.** *Public Health* 2020; 185:199-201 Das A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653628>
  73. **High altitude reduces infection rate of COVID-19 but not case-fatality rate.** *Respir. Physiol. Neurobiol.* 2020;103494 Segovia-Juarez J, Castagnetto JM, Gonzales GF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679369>
  74. **[Effectiveness of the implementation of clinical-epidemiological management during Covid-19 in a medium-long-stay hospital.].** *Rev. Esp. Salud Publica* 2020; 94 Ruiz Moruno AJ, Rodriguez Cola M, Jimenez Velasco I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655128>
  75. **Do the Benefits of COVID-19 Policies Exceed the Costs? Exploring Uncertainties in the Age-VSL Relationship.** *Risk Anal.* 2020; Robinson LA, Sullivan R, Shogren JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677076>
  76. **SARS-CoV-2 in river water: Implications in low sanitation countries.** *Sci Total Environ* 2020; 743:140832 Guerrero-Latorre L, Ballesteros I, Villacres-Granda I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679506>
  77. **Wastewater surveillance for Covid-19: An African perspective.** *Sci Total Environ* 2020; 743:140719 Street R, Malema S, Mahlangeni N, Mathee A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659559>
  78. **Discordant courses of COVID-19 in a cohabiting couple of lung transplant recipients.** *Transpl Infect Dis* 2020; e13410 Desmazes-Dufeu N, Coltey B, Amari L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654244>
  79. **Emerging coronavirus diseases and future perspectives.** *Virusdisease* 2020; 31:113-120 Akhter S, Akhtar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656308>
  80. **Decoding the global outbreak of COVID-19: the nature is behind the scene.** *Virusdisease* 2020; 31:106-112 Das P, Choudhuri T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656307>
  81. **Statistical analysis and visualization of the potential cases of pandemic coronavirus.** *Virusdisease* 2020; 31:204-208 Muthusami R, Saritha K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656312>
  82. **What settings have been linked to SARS-CoV-2 transmission clusters? Wellcome Open Res** 2020; 5:83 Leclerc QJ, Fuller NM, Knight LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656368>
  83. **[Application of healthcare big data in active case finding of COVID-19 in Yinzhou district of Ningbo].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E075 Sun YX, Lyu J, Shen P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654429>

## Management (75 articles)

1. **ESPEN Expert Statements and Practical Guidance for Nutritional Management of Individuals with SARS-CoV-2 Infection.** *Aktuelle Ernährungsmedizin* 2020; 45:182-192 Barazzoni R, Bischoff SC, Breda J *et al.*
2. **Reply to Jakovac: COVID-19, vitamin D, and type I interferon.** *Am J Physiol Endocrinol Metab* 2020; 319:E245-e246 Gauzzi MC, Fantuzzi L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672049>
3. **Reply to: Inhaled Corticosteroids and COVID-19.** *Am J Respir Crit Care Med* 2020; Maes T, Bracke K, Brusselle GG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668164>
4. **Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?** *Anaesth Crit Care Pain Med* 2020; Bendjelid K, Giraud R, During SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653550>
5. **COVID-19 pandemic and limited palliative care response: "Lack of comfort care".** *Anaesth Crit Care Pain Med* 2020; Sirohiya P, Ratre B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653546>
6. **Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.** *BMC Med* 2020; 18:215 Ostuzzi G, Papola D, Gastaldon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664944>
7. **Airway management lessons from case reports of negative outcomes. Comment on Br J Anaesth; 125: e168-70.** *Br J Anaesth* 2020; Heidegger T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680606>
8. **Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.** *Chin J Integr Med* 2020; Wang JB, Wang ZX, Jing J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676976>
9. **Immunopathogenesis of COVID-19 and early immunomodulators.** *Clin Exp Pediatr* 2020; 63:239-250 Lee KY, Rhim JW, Kang JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664709>
10. **Response System for and Epidemiological Features of COVID-19 in Gyeongsangnam-do Province in South Korea.** *Clin Infect Dis* 2020; Wi YM, Lim SJ, Kim SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672789>
11. **Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome.** *Crit Care* 2020; 24:428 Garcia B, Cousin N, Bourel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665007>
12. **Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study.** *Crit Care* 2020; 24:429 Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664990>
13. **Current Status of the COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy.** *Curr. Pharm. Des.* 2020; Behl T, Rahman MH, Akter R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660401>
14. **Current Status of the COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy.** *Curr. Pharm. Des.* 2020; Rahman MH, Akter R, Behl T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660401>
15. **Development and implementation of an operational concept in a university eye hospital in the SARS-CoV-2 pandemic.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Singh P, Müller M, Hack D *et al.*



16. **Adaptation of Coronavirus (COVID-19) protocols to a Parisian maternity unit during the 2020 pandemic: a managerial perspective.** Disaster Med Public Health Prep 2020;1-10Ghanchi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660662>
17. **COVID-19 and ENT surgery: a brief review of essential precautions and triage.** Eur Arch Otorhinolaryngol 2020; Sharma A, Bhardwaj R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654024>
18. **Clinical presentation and outcome across age categories among patients with COVID-19 admitted to a Spanish Emergency Department.** Eur. Geriatr. Med. 2020; Martin-Sanchez FJ, Del Toro E, Cardassay E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671732>
19. **Exercise and well-being during COVID 19 - Time to boost your immunity.** Expert Rev. Anti Infect. Ther. 2020; Ranasinghe C, Ozemek C, Arena R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662717>
20. **Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol.** Front Med (Lausanne) 2020; 7:372Azabou E, Bao G, Heming N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671084>
21. **Special Attention to Diet and Physical Activity in Children and Adolescents With Obesity During the Coronavirus Disease-2019 Pandemic.** Front Pediatr 2020; 8:407Calcaterra V, Vandoni M, Pellino VC, Cena H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676491>
22. **Governing COVID-19 without government in Brazil: Ignorance, neoliberal authoritarianism, and the collapse of public health leadership.** Glob Public Health 2020;1-21Ortega F, Orsini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663117>
23. **Misinformation and de-contextualization: international media reporting on Sweden and COVID-19.** Global Health 2020; 16:62Irwinn RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660503>
24. **A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.** Harm Reduct J 2020; 17:49Crowley D, Delargy I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680520>
25. **Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response.** Health Res. Policy Syst. 2020; 18:80Kringos D, Carinci F, Barbazza E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664985>
26. **Vitamin D and COVID-19.** Hormones (Athens) 2020; Trovas G, Tournis S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666357>
27. **CUPID COVID-19: emergency department attendance by paediatric patients during COVID-19 - project protocol.** HRB Open Res 2020; 3:37McDonnell T, McAuliffe E, Barrett M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666040>
28. **Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response.** Immunol. Lett. 2020; 226:38-45Hannan MA, Rahman MA, Rahman MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659267>
29. **COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.** Immunol. Res. 2020; Perricone C, Bartoloni E, Bursi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681497>
30. **Obesity, COVID-19 and immunotherapy: the complex relationship!** Immunotherapy 2020; Finelli C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677493>
31. **Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic.** Int. J. Clin. Oncol. 2020; Aznab M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654049>
32. **COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?** Int. J. Vitam. Nutr. Res. 2020;1-2Alshahawey M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674673>
33. **The lady with the lamp: Amid the COVID-19 haze.** Int Nurs Rev 2020; Xiao Y, Jiang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677081>
34. **COVID-19 pandemic: management of patients affected by SARS-CoV-2 in Rome COVID Hospital 2 Trauma Centre and safety of our surgical team.** Int. Orthop. 2020; De Mauro D, Rovere G, Smimmo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671432>
35. **Multidisciplinary Care of Epidermolysis Bullosa during the COVID-19 Pandemic - Consensus: Recommendations by an International Panel of Experts.** J Am Acad Dermatol 2020; Murrell DF, Lucky AW, Salas-Alanis JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682031>
36. **Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?** J Am Coll Cardiol 2020; 76:277-279Bloch MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674791>
37. **The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.** J. Am. Med. Dir. Assoc. 2020; 21:909-914.e902De Spiegeleer A, Bronselaer A, Teo JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674818>
38. **A Structured Tool for Communication and Care Planning in the Era of the COVID-19 Pandemic.** J. Am. Med. Dir. Assoc. 2020; 21:943-947Gaur S, Pandya N, Dumyati G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674824>
39. **How a Barcelona Post-Acute Facility became a Referral Center for Comprehensive Management of Subacute Patients With COVID-19.** J. Am. Med. Dir. Assoc. 2020; 21:954-957Inzitari M, Udina C, Len O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674827>
40. **Solving the COVID-19 Crisis in Post-Acute and Long-Term Care.** J. Am. Med. Dir. Assoc. 2020; 21:885-887Laxton CE, Nace DA, Nazir A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674813>
41. **Policy Recommendations Regarding Skilled Nursing Facility Management of Coronavirus 19 (COVID-19): Lessons from New York State.** J. Am. Med. Dir. Assoc. 2020; 21:888-892Lester PE, Holahan T, Siskind D, Healy E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674814>
42. **Fever, flu and family physicians during COVID 19 pandemic 2020 in India.** J Family Med Prim Care 2020; 9:1781-1783Kumar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670916>
43. **Ensuring continuity of care by small family practices and clinics in the primary care setting during COVID 19 pandemic 2020 - A position paper by the Academy of Family Physicians of India.** J Family Med Prim Care 2020; 9:1798-1800Kumar R, Boobna V, Kubendra M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670920>
44. **Aging and Therapy-Related Hypogammaglobulinemia causing Pneumonia: An Overlooked Curable Entity in the Chaotic COVID-19 Pandemic.** J Med Virol 2020; Zaidi SZA, Zaidi FZ, AIShehry N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681654>
45. **Experiences of clinical first-line nurses treating patients with COVID-19: A qualitative study.** J. Nurs. Manag. 2020; Tan R, Yu T, Luo K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657465>



46. **Guidelines for Frontline Health Care Staff Safety for COVID-19.** *J. Prim. Care Community Health* 2020; 11:2150132720938046 Baker TL, Greiner JV, Maxwell-Schmidt E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659152>
47. **Fish Oil and Covid-19 Thromboses.** *J Vasc Surg Venous Lymphat Disord* 2020; Merritt RJ, Bhardwaj V, Jami MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682081>
48. **Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.** *J Xray Sci Technol* 2020; Su Y, Han Y, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675436>
49. **Tackling the cytokine storm in COVID-19, challenges, and hopes.** *Life Sci* 2020;118054 Abdin SM, Elgendy SM, Alyammahi SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663575>
50. **Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis? Med. Hypotheses** 2020; 143:110018 Tastemur S, Ataseven H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679422>
51. **Clinical presentation and management of COVID-19.** *Med. J. Aust.* 2020; Thevarajan I, Buising KL, Cowie BC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677734>
52. **[Recommendations for resource management in intensive care units during the COVID-19 pandemic].** *Medicina (B. Aires)* 2020; 80 Suppl 3:67-76 Arias-Lopez MDP, Mandich V, Mosciaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658850>
53. **[COVID-19 in the intensive care unit. Analysis of the experience during the first month of pandemic].** *Medicina (B. Aires)* 2020; 80 Suppl 3:25-30 Carboni Bisso I, Huespe I, Lockhart C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658844>
54. **[Ethical guides, criteria for admission in intensive care, palliative care. Multi-society recommendations for allocation of resources during the COVID-19 pandemic].** *Medicina (B. Aires)* 2020; 80 Suppl 3:45-64 Maglio I, Valdez P, Camera L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658848>
55. **[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].** *Medicina (B. Aires)* 2020; 80 Suppl 3:65-66 Vazquez FJ, Korin J, Baldessari EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658849>
56. **Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020044 Malek AE, Gutierrez C, Mulanovich VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670522>
57. **Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the COVID-19 Pandemic: An Iranian Consensus.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020050 Mousavi SA, Rad S, Rostami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670528>
58. **Nursing Division on the current intensive care situation in Germany: Working group of the Nursing Division of the German Society of Medical Intensive Care and Emergency Medicine (DGIIN).** *Medizinische Klinik - Intensivmedizin und Notfallmedizin* 2020; Hermes C, Ochmann T.
59. **Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.** *Mult Scler Relat Disord* 2020; 44:102353 Viswanathan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653804>
60. **A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients.** *Neurol Sci* 2020; Sangalli D, Polonia V, Colombo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656711>
61. **ASPEN Report on Nutrition Support Practice Processes With COVID-19: The First Response.** *Nutr. Clin. Pract.* 2020; Wells Mulherin D, Walker R, Holcombe B, Guenter P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671870>
62. **Supplementation with vitamin D in the COVID-19 pandemic?** *Nutr. Rev.* 2020; Hadizadeh F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679589>
63. **The Early Food Insecurity Impacts of COVID-19.** *Nutrients* 2020; 12:Niles MT, Bertmann F, Belarmino EH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679788>
64. **An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2.** *Open Forum Infect Dis* 2020; 7:ofaa232 Schiffer JT, Johnston C, Wald A, Corey L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661497>
65. **Reduced demand for oral diagnosis during COVID-19: a Brazilian center experience.** *Oral Dis* 2020; Gomes APN, Schuch LF, Tarquinio SBC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654221>
66. **COVID-19 Airway Management Isolation Chamber.** *Otolaryngol Head Neck Surg* 2020;194599820942500 Blood TC, Jr., Perkins JN, Wistermayer PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662735>
67. **Perioperative management of COVID-19 patients undergoing cardiac surgery with cardiopulmonary bypass.** *Perfusion* 2020;267659120941341 Gunaydin S, Stammers AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666887>
68. **Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.** *Pharmacol. Ther.* 2020;107628 Wang JJ, Edin ML, Zeldin DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653530>
69. **Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19: German Respiratory Society.** *Pneumologie* 2020; 74:337-357 Pfeifer M, Pfeifer M, Pfeifer M *et al.*
70. **Responsibilities of Weaning Centers during the COVID-19 Pandemic Outbreak: Recommendations for the Assignment of ICU Capacities in COVID-19 Patients as shown by the Berlin-Brandenburg POST-SAVE-Model.** *Pneumologie* 2020; 74:358-365 Wiesner B, Bachmann M, Blum TG *et al.*
71. **Caring for Loved Ones with Cancer during the COVID-19 Pandemic: A Double Hit Risk for Social Isolation and Need for Action.** *Psychooncology* 2020; Sannes TS, Yeh IM, Gray TF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658360>
72. **Pros and cons of corticosteroid therapy for COVID-19 patients.** *Respir. Physiol. Neurobiol.* 2020;103492 Mattos-Silva P, Felix NS, Silva PL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659271>
73. **[Effectiveness of the implementation of clinical-epidemiological management during Covid-19 in a medium-long-stay hospital.].** *Rev. Esp. Salud Publica* 2020; 94 Ruiz Moruno AJ, Rodriguez Cola M, Jimenez Velasco I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655128>
74. **Systematic Application of Rapid Sequence Intubation With Remifentanyl During COVID-19 Pandemic.** *Semin. Cardiothorac. Vasc. Anesth.* 2020;1089253220941369 Bevilacqua S, Bottari V, Galeotti I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664787>

75. **Breath Regulation and yogic Exercise An online Therapy for calm and Happiness (BREATH) for frontline hospital and long-term care home staff managing the COVID-19 pandemic: A structured summary of a study protocol for a feasibility study for a randomised controlled trial.** *Trials* 2020; 21:648Lai KSP, Watt C, Ionson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665041>

## Mental – public health (75 articles)

1. **ESPEN Expert Statements and Practical Guidance for Nutritional Management of Individuals with SARS-CoV-2 Infection.** *Aktuelle Ernährungsmedizin* 2020; 45:182-192Barazzoni R, Bischoff SC, Breda J *et al.*
2. **Reply to Jakovac: COVID-19, vitamin D, and type I interferon.** *Am J Physiol Endocrinol Metab* 2020; 319:E245-e246Gauzzi MC, Fantuzzi L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672049>
3. **Reply to: Inhaled Corticosteroids and COVID-19.** *Am J Respir Crit Care Med* 2020; Maes T, Bracke K, Brusselle GG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668164>
4. **Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?** *Anaesth Crit Care Pain Med* 2020; Bendjelid K, Giraud R, During SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653550>
5. **COVID-19 pandemic and limited palliative care response: "Lack of comfort care".** *Anaesth Crit Care Pain Med* 2020; Sirohiya P, Ratre B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653546>
6. **Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.** *BMC Med* 2020; 18:215Ostuzzi G, Papola D, Gastaldon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664944>
7. **Airway management lessons from case reports of negative outcomes. Comment on Br J Anaesth; 125: e168-70.** *Br J Anaesth* 2020; Heidegger T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680606>
8. **Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.** *Chin J Integr Med* 2020; Wang JB, Wang ZX, Jing J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676976>
9. **Immunopathogenesis of COVID-19 and early immunomodulators.** *Clin Exp Pediatr* 2020; 63:239-250Lee KY, Rhim JW, Kang JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664709>
10. **Response System for and Epidemiological Features of COVID-19 in Gyeongsangnam-do Province in South Korea.** *Clin Infect Dis* 2020; Wi YM, Lim SJ, Kim SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672789>
11. **Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome.** *Crit Care* 2020; 24:428Garcia B, Cousin N, Bourel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665007>
12. **Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study.** *Crit Care* 2020; 24:429Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664990>
13. **Current Status of the COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy.** *Curr. Pharm. Des.* 2020; Behl T, Rahman MH, Akter R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660401>
14. **Current Status of the COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy.** *Curr. Pharm. Des.* 2020; Rahman MH, Akter R, Behl T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660401>
15. **Development and implementation of an operational concept in a university eye hospital in the SARS-CoV-2 pandemic.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Singh P, Müller M, Hack D *et al.*
16. **Adaptation of Coronavirus (COVID-19) protocols to a Parisian maternity unit during the 2020 pandemic: a managerial perspective.** *Disaster Med Public Health Prep* 2020:1-10Ghanchi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660662>
17. **COVID-19 and ENT surgery: a brief review of essential precautions and triage.** *Eur Arch Otorhinolaryngol* 2020; Sharma A, Bhardwaj R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654024>
18. **Clinical presentation and outcome across age categories among patients with COVID-19 admitted to a Spanish Emergency Department.** *Eur. Geriatr. Med.* 2020; Martin-Sanchez FJ, Del Toro E, Cardassay E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671732>
19. **Exercise and well-being during COVID 19 - Time to boost your immunity.** *Expert Rev. Anti Infect. Ther.* 2020; Ranasinghe C, Ozemek C, Arena R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662717>
20. **Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol.** *Front Med (Lausanne)* 2020; 7:372Azabou E, Bao G, Heming N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671084>
21. **Special Attention to Diet and Physical Activity in Children and Adolescents With Obesity During the Coronavirus Disease-2019 Pandemic.** *Front Pediatr* 2020; 8:407Calcaterra V, Vandoni M, Pellino VC, Cena H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676491>
22. **Governing COVID-19 without government in Brazil: Ignorance, neoliberal authoritarianism, and the collapse of public health leadership.** *Glob Public Health* 2020:1-21Ortega F, Orsini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663117>
23. **Misinformation and de-contextualization: international media reporting on Sweden and COVID-19.** *Global Health* 2020; 16:62Irwin RE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660503>
24. **A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.** *Harm Reduct J* 2020; 17:49Crowley D, Delargy I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680520>
25. **Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response.** *Health Res. Policy Syst.* 2020; 18:80Kringos D, Carinci F, Barbazza E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664985>
26. **Vitamin D and COVID-19.** *Hormones (Athens)* 2020; Trovas G, Tournis S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666357>
27. **CUPID COVID-19: emergency department attendance by paediatric patients during COVID-19 - project protocol.** *HRB Open Res* 2020; 3:37McDonnell T, McAuliffe E, Barrett M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666040>

28. **Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response.** *Immunol. Lett.* 2020; 226:38-45Hannan MA, Rahman MA, Rahman MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659267>
29. **COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.** *Immunol. Res.* 2020; Perricone C, Bartoloni E, Bursi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681497>
30. **Obesity, COVID-19 and immunotherapy: the complex relationship!** *Immunotherapy* 2020; Finelli C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677493>
31. **Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic.** *Int. J. Clin. Oncol.* 2020; Aznab M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654049>
32. **COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?** *Int. J. Vitam. Nutr. Res.* 2020;1-2Alshahawey M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674673>
33. **The lady with the lamp: Amid the COVID-19 haze.** *Int Nurs Rev* 2020; Xiao Y, Jiang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677081>
34. **COVID-19 pandemic: management of patients affected by SARS-CoV-2 in Rome COVID Hospital 2 Trauma Centre and safety of our surgical team.** *Int. Orthop.* 2020; De Mauro D, Rovere G, Smimmo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671432>
35. **Multidisciplinary Care of Epidermolysis Bullosa during the COVID-19 Pandemic - Consensus: Recommendations by an International Panel of Experts.** *J Am Acad Dermatol* 2020; Murrell DF, Lucky AW, Salas-Alanis JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682031>
36. **Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?** *J Am Coll Cardiol* 2020; 76:277-279Bloch MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674791>
37. **The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.** *J. Am. Med. Dir. Assoc.* 2020; 21:909-914.e902De Spiegeleer A, Bronselaer A, Teo JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674818>
38. **A Structured Tool for Communication and Care Planning in the Era of the COVID-19 Pandemic.** *J. Am. Med. Dir. Assoc.* 2020; 21:943-947Gaur S, Pandya N, Dumyati G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674824>
39. **How a Barcelona Post-Acute Facility became a Referral Center for Comprehensive Management of Subacute Patients With COVID-19.** *J. Am. Med. Dir. Assoc.* 2020; 21:954-957Inzitari M, Udina C, Len O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674827>
40. **Solving the COVID-19 Crisis in Post-Acute and Long-Term Care.** *J. Am. Med. Dir. Assoc.* 2020; 21:885-887Laxton CE, Nace DA, Nazir A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674813>
41. **Policy Recommendations Regarding Skilled Nursing Facility Management of Coronavirus 19 (COVID-19): Lessons from New York State.** *J. Am. Med. Dir. Assoc.* 2020; 21:888-892Lester PE, Holahan T, Siskind D, Healy E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674814>
42. **Fever, flu and family physicians during COVID 19 pandemic 2020 in India.** *J Family Med Prim Care* 2020; 9:1781-1783Kumar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670916>
43. **Ensuring continuity of care by small family practices and clinics in the primary care setting during COVID 19 pandemic 2020 - A position paper by the Academy of Family Physicians of India.** *J Family Med Prim Care* 2020; 9:1798-1800Kumar R, Boobna V, Kubendra M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670920>
44. **Aging and Therapy-Related Hypogammaglobulinemia causing Pneumonia: An Overlooked Curable Entity in the Chaotic COVID-19 Pandemic.** *J Med Virol* 2020; Zaidi SZA, Zaidi FZ, AlShehry N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681654>
45. **Experiences of clinical first-line nurses treating patients with COVID-19: A qualitative study.** *J. Nurs. Manag.* 2020; Tan R, Yu T, Luo K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657465>
46. **Guidelines for Frontline Health Care Staff Safety for COVID-19.** *J. Prim. Care Community Health* 2020; 11:2150132720938046Baker TL, Greiner JV, Maxwell-Schmidt E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659152>
47. **Fish Oil and Covid-19 Thromboses.** *J Vasc Surg Venous Lymphat Disord* 2020; Merritt RJ, Bhardwaj V, Jami MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682081>
48. **Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.** *J Xray Sci Technol* 2020; Su Y, Han Y, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675436>
49. **Tackling the cytokine storm in COVID-19, challenges, and hopes.** *Life Sci* 2020:118054Abdin SM, Elgendy SM, Alyammahi SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663575>
50. **Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?** *Med. Hypotheses* 2020; 143:110018Tastemur S, Ataseven H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679422>
51. **Clinical presentation and management of COVID-19.** *Med. J. Aust.* 2020; Thevarajan I, Buising KL, Cowie BC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677734>
52. **[Recommendations for resource management in intensive care units during the COVID-19 pandemic].** *Medicina (B. Aires)* 2020; 80 Suppl 3:67-76Arias-Lopez MDP, Mandich V, Mosciaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658850>
53. **[COVID-19 in the intensive care unit. Analysis of the experience during the first month of pandemic].** *Medicina (B. Aires)* 2020; 80 Suppl 3:25-30Carboni Bisso I, Huespe I, Lockhart C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658844>
54. **[Ethical guides, criteria for admission in intensive care, palliative care. Multi-society recommendations for allocation of resources during the COVID-19 pandemic].** *Medicina (B. Aires)* 2020; 80 Suppl 3:45-64Maglio I, Valdez P, Camera L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658848>
55. **[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].** *Medicina (B. Aires)* 2020; 80 Suppl 3:65-66Vazquez FJ, Korin J, Baldessari EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658849>
56. **Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020044Malek AE, Gutierrez C, Mulanovich VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670522>
57. **Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the COVID-19 Pandemic: An Iranian Consensus.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020050Mousavi SA, Rad



- S, Rostami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670528>
58. **Nursing Division on the current intensive care situation in Germany: Working group of the Nursing Division of the German Society of Medical Intensive Care and Emergency Medicine (DGIIN).** *Medizinische Klinik - Intensivmedizin und Notfallmedizin* 2020; Hermes C, Ochmann T.
  59. **Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.** *Mult Scler Relat Disord* 2020; 44:102353Viswanathan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653804>
  60. **A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients.** *Neurol Sci* 2020; Sangalli D, Polonia V, Colombo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656711>
  61. **ASPEN Report on Nutrition Support Practice Processes With COVID-19: The First Response.** *Nutr. Clin. Pract.* 2020; Wells Mulherin D, Walker R, Holcombe B, Guenter P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671870>
  62. **Supplementation with vitamin D in the COVID-19 pandemic?** *Nutr. Rev.* 2020; Hadizadeh F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679589>
  63. **The Early Food Insecurity Impacts of COVID-19.** *Nutrients* 2020; 12Niles MT, Bertmann F, Belarmino EH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679788>
  64. **An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2.** *Open Forum Infect Dis* 2020; 7:ofaa232Schiffer JT, Johnston C, Wald A, Corey L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661497>
  65. **Reduced demand for oral diagnosis during COVID-19: a Brazilian center experience.** *Oral Dis* 2020; Gomes APN, Schuch LF, Tarquinio SBC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654221>
  66. **COVID-19 Airway Management Isolation Chamber.** *Otolaryngol Head Neck Surg* 2020:194599820942500Blood TC, Jr., Perkins JN, Wistermayer PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662735>
  67. **Perioperative management of COVID-19 patients undergoing cardiac surgery with cardiopulmonary bypass.** *Perfusion* 2020:267659120941341Gunaydin S, Stammers AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666887>
  68. **Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.** *Pharmacol. Ther.* 2020:107628Wang JJ, Edin ML, Zeldin DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653530>
  69. **Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19: German Respiratory Society.** *Pneumologie* 2020; 74:337-357Pfeifer M, Pfeifer M, Pfeifer M *et al.*
  70. **Responsibilities of Weaning Centers during the COVID-19 Pandemic Outbreak: Recommendations for the Assignment of ICU Capacities in COVID-19 Patients as shown by the Berlin-Brandenburg POST-SAVE-Model.** *Pneumologie* 2020; 74:358-365Wiesner B, Bachmann M, Blum TG *et al.*
  71. **Caring for Loved Ones with Cancer during the COVID-19 Pandemic: A Double Hit Risk for Social Isolation and Need for Action.** *Psychooncology* 2020; Sannes TS, Yeh IM, Gray TF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658360>
  72. **Pros and cons of corticosteroid therapy for COVID-19 patients.** *Respir. Physiol. Neurobiol.* 2020:103492Mattos-Silva P, Felix NS, Silva PL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659271>
  73. **[Effectiveness of the implementation of clinical-epidemiological management during Covid-19 in a medium-long-stay hospital.]** *Rev. Esp. Salud Publica* 2020; 94Ruiz Moruno AJ, Rodriguez Cola M, Jimenez Velasco I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655128>
  74. **Systematic Application of Rapid Sequence Intubation With Remifentanyl During COVID-19 Pandemic.** *Semin. Cardiothorac. Vasc. Anesth.* 2020:1089253220941369Bevilacqua S, Bottari V, Galeotti I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664787>
  75. **Breath Regulation and yogic Exercise An online Therapy for calm and Happiness (BREATH) for frontline hospital and long-term care home staff managing the COVID-19 pandemic: A structured summary of a study protocol for a feasibility study for a randomised controlled trial.** *Trials* 2020; 21:648Lai KSP, Watt C, Lonson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665041>

## Meta-analyses - systematic reviews (14 articles)

1. **Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis.** *Aging (Albany NY)* 2020; 12Fang X, Li S, Yu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658868>
2. **Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis.** *Crit Care* 2020; 24:439Chen YT, Shao SC, Lai EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677972>
3. **Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool.** *Egypt Heart J* 2020; 72:41Momtazmanesh S, Shobeiri P, Hanaei S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661796>
4. **Systematic Review and Meta-Analysis of Sex-Specific COVID-19 Clinical Outcomes.** *Front Med (Lausanne)* 2020; 7:348Galbadage T, Peterson BM, Awada J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671082>
5. **Neurological and Musculoskeletal Features of COVID-19: A Systematic Review and Meta-Analysis.** *Front. Neurol.* 2020; 11:687Abdullahi A, Candan SA, Abba MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676052>
6. **Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis.** *Int J Environ Res Public Health* 2020; 17Ghayda RA, Lee J, Lee JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668763>
7. **Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis.** *J. Affect. Disord.* 2020; 275:48-57Salazar de Pablo G, Vaquerizo-Serrano J, Catalan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658823>
8. **The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects.** *J. Am. Med. Dir. Assoc.* 2020; 21:915-918Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674819>
9. **Hemostatic Changes in Patients with COVID-19: A Meta-Analysis with Meta-Regressions.** *J Clin Med* 2020; 9Di Minno MND, Calcaterra I, Lupoli R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679766>

10. **Considerations on COVID-19 pregnancy: a cases series during outbreak in Bergamo Province, North Italy.** *J Matern Fetal Neonatal Med* 2020;1-4Algeri P, Stagnati V, Spazzini MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664761>
11. **Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: a systematic review and meta-analysis.** *J Med Virol* 2020; Zarifian A, Bidary MZ, Arekhi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681674>
12. **Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis.** *Microb. Pathog.* 2020;104390Pormohammad A, Ghorbani S, Baradaran B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681968>
13. **Olfactory Training for Postviral Olfactory Dysfunction: Systematic Review and Meta-analysis.** *Otolaryngol Head Neck Surg* 2020;194599820943550Kattar N, Do TM, Unis GD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660334>
14. **Trends in clinical features of novel coronavirus disease (COVID-19): A systematic review and meta-analysis of studies published from December 2019 to February 2020.** *Respir Investig* 2020; Manabe T, Akatsu H, Kotani K, Kudo K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653383>

## Mortality (20 articles)

1. **Comparing associations between frailty and mortality in hospitalised older adults with or without COVID-19 infection: a retrospective observational study using electronic health records.** *Age Ageing* 2020; Owen RK, Conroy SP, Taub N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678866>
2. **Global Incidence and Mortality Rate of COVID-19; Special Focus on Iran, Italy and China.** *Arch Iran Med* 2020; 23:455-461Chaibakhsh S, Pourhoseingholi A, Vahedi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657596>
3. **Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis.** *Crit Care* 2020; 24:439Chen YT, Shao SC, Lai EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677972>
4. **Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.** *Crit Care* 2020; 24:438Zhang S, Guo M, Duan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678040>
5. **Higher testing coverage is associated with lower COVID-19 mortality rate: insights from Italian regions.** *Disaster Med Public Health Prep* 2020;1-11Saglietto A, Moirano G, Anselmino M, De Ferrari GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660686>
6. **Clinical features of fatalities in patients with COVID-19.** *Disaster Med Public Health Prep* 2020;1-10Sun YJ, Feng YJ, Chen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665052>
7. **Temporal association between particulate matter pollution and case fatality rate of COVID-19 in Wuhan.** *Environ. Res.* 2020; 189:109941Yao Y, Pan J, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678728>
8. **Can Vitamin D and L-Cysteine Co-Supplementation Reduce 25(OH)-Vitamin D Deficiency and the Mortality Associated with COVID-19 in African Americans?** *J. Am. Coll. Nutr.* 2020;1-6Jain SK, Parsanathan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659175>
9. **The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects.** *J. Am. Med. Dir. Assoc.* 2020; 21:915-918Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674819>
10. **Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study.** *J. Am. Med. Dir. Assoc.* 2020; 21:928-932.e921De Smet R, Mellaerts B, Vandewinckele H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674821>
11. **Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19.** *J. Clin. Lab. Anal.* 2020:e23467Chen X, Yan L, Fei Y, Zhang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656888>
12. **The Impact of COVID-19 Global Pandemic on Morbidity and Mortality of Liver Transplant Recipients Children and Adults: A Systematic Review of Case Series.** *J. Clin. Med. Res.* 2020; 12:404-408Gavriilidis P, Pai M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655733>
13. **Diabetes Mellitus Association with Coronavirus Disease 2019 (COVID-19) Severity and Mortality: A Pooled Analysis.** *J. Diabetes* 2020; Aggarwal G, Lippi G, Lavie CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677321>
14. **Factors Leading to High Morbidity and Mortality of COVID-19 in Patients with Type 2 Diabetes.** *J. Diabetes* 2020; Rajpal A, Rahimi L, Ismail-Beigi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671936>
15. **Mortality of high-risk orthopaedic oncology patients during the COVID-19 pandemic: A prospective cohort study.** *J. Surg. Oncol.* 2020; Stevenson JD, Evans S, Morris G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668015>
16. **Oscillations in U.S. COVID-19 Incidence and Mortality Data Reflect Diagnostic and Reporting Factors.** *mSystems* 2020; 5Bergman A, Sella Y, Agre P, Casadevall A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665331>
17. **Obesity and mortality of COVID-19. Meta-analysis.** *Obes. Res. Clin. Pract.* 2020; Hussain A, Mahawar K, Xia Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660813>
18. **Risk factors for lethal clinical courses of COVID-19 in China.** *Pneumologie* 2020; 74:324-325Klein F.
19. **Patterns of mortality during pandemic: An example of Spanish flu pandemic of 1918.** *Popul Econ* 2020; 4:56-64Gavrilova NS, Gavrilov LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656548>
20. **Germany's first COVID-19 deceased: a 59-year-old man presenting with diffuse alveolar damage due to SARS-CoV-2 infection.** *Virchows Arch.* 2020; Heinrich F, Sperhake JP, Heinemann A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666230>

## Online – IT – Apps (35 articles)

1. **Otolaryngology-related Google Search trends during the COVID-19 pandemic.** *Am. J. Otolaryngol.* 2020; 41:102615Pier MM, Pasick LJ, Benito DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659612>
2. **Reinventing How Pharmacy Educators Connect as a Community.** *Am. J. Pharm. Educ.* 2020; 84:ajpe8151Sorensen TD, Lin A, Allen DD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665724>
3. **Inter Organizational Practice Committee Recommendations/Guidance for Teleneuropsychology in Response to the COVID-19 Pandemic***dagger.* *Arch. Clin. Neuropsychol.* 2020; Bilder RM, Postal KS, Barisa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666093>
4. **Moving the human biology program from face-to-face to online delivery mode in the time of COVID-19.** *Biochem Mol Biol Educ* 2020; Papanephytous C, Stavridis P, Nicolaou SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681803>
5. **Machine learning to assist clinical decision-making during the COVID-19 pandemic.** *Bioelectron Med* 2020; 6:14Debnath S, Barnaby DP, Coppa K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665967>
6. **Development of a semi-structured, multifaceted, computer-aided questionnaire for outbreak investigation: e-Outbreak Platform.** *Biomed J* 2020; Chen WJ, Yang SY, Chang JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654885>
7. **Feasibility of a 5G-based robot-assisted remote ultrasound system for cardiopulmonary assessment of COVID-19 patients.** *Chest* 2020; Ye R, Zhou X, Shao F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653568>
8. **Virtual Health During a Pandemic: Redesigning Care to Protect Our Most Vulnerable Patients.** *Circ Heart Fail* 2020;Circheartfailure120007317Almufleh A, Givertz MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673503>
9. **InterOrganizational practice committee recommendations/guidance for teleneuropsychology (TeleNP) in response to the COVID-19 pandemic.** *Clin. Neuropsychol.* 2020:1-21Bilder RM, Postal KS, Barisa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673163>
10. **CovXNet: A multi-dilation convolutional neural network for automatic COVID-19 and other pneumonia detection from chest X-ray images with transferable multi-receptive feature optimization.** *Comput. Biol. Med.* 2020; 122:103869Mahmud T, Rahman MA, Fattah SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658740>
11. **Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans.** *Comput. Biol. Med.* 2020; 122:103849Robson B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658736>
12. **Interventional cytopathology in COVID-19 ERA.** *Cytopathology* 2020; Ronchi A, Pagliuca F, Zito Marino F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654199>
13. **The Development of an Epilepsy Electronic Patient Portal: Facilitating both patient empowerment and remote clinician-patient interaction in a post COVID-19 world.** *Epilepsia* 2020; Power K, McCrea Z, White M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668026>
14. **Telemedicine and Smart Working: Recommendations of the European Association of Urology.** *Eur. Urol.* 2020; Rodriguez Socarras M, Loeb S, Teoh JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654801>
15. **Emerging technologies for diagnostics and drug delivery in the fight against COVID-19 and other pandemics.** *Expert Rev. Med. Devices* 2020:1-6Lamprou DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674622>
16. **Accelerating Telemedicine for Cerebral Palsy During the COVID-19 Pandemic and Beyond.** *Front. Neurol.* 2020; 11:746Ben-Pazi H, Beni-Adani L, Lamdan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670193>
17. **Telemedicine for the Spine Surgeon in the Age of COVID-19: Multicenter Experiences of Feasibility and Implementation Strategies.** *Global Spine J* 2020:2192568220932168Franco D, Montenegro T, Gonzalez GA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677513>
18. **A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.** *Harm Reduct J* 2020; 17:49Crowley D, Delargy I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680520>
19. **Using Information Technology To Improve COVID-19 Care At New York City Health + Hospitals.** *Health Aff (Millwood)* 2020:101377h1thaff202000930Salway RJ, Silvestri D, Wei E, Bouton M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673131>
20. **Personalizing symptom monitoring and contact tracing efforts through a COVID-19 web-app.** *Infect Dis Poverty* 2020; 9:93Yap KY, Xie Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660568>
21. **Increase in Video Consultations During the COVID-19 Pandemic: Healthcare Professionals' Perceptions about Their Implementation and Adequate Management.** *Int J Environ Res Public Health* 2020; 17Jimenez-Rodriguez D, Santillan Garcia A, Montoro Robles J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679848>
22. **A Structured Tool for Communication and Care Planning in the Era of the COVID-19 Pandemic.** *J. Am. Med. Dir. Assoc.* 2020; 21:943-947Gaur S, Pandya N, Dumyati G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674824>
23. **Reducing Social Isolation of Seniors during COVID-19 through Medical Student Telephone Contact.** *J. Am. Med. Dir. Assoc.* 2020; 21:948-950Office EE, Rodenstein MS, Merchant TS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674825>
24. **Home telemonitoring makes early hospital discharge of COVID-19 patients possible.** *J Am Med Inform Assoc* 2020; Grutters LA, Majoor KI, Mattern ESK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667985>
25. **5G Technology and induction of coronavirus in skin cells.** *J Biol Regul Homeost Agents* 2020; 34Fioranelli M, Sepehri A, Rocca MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668870>
26. **Medicine 4.0: New Technologies as Tools for a Society 5.0.** *J Clin Med* 2020; 9Ioppolo G, Vazquez F, Hennerici MG, Andres E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664634>
27. **Online interprofessional education during and post the COVID-19 pandemic: a commentary.** *J Interprof Care* 2020:1-4Khalili H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674721>
28. **The New Normal: Patient-Physician Relationships During COVID-19.** *Methodist Debaquey Cardiovasc. J.* 2020; 16:181-182Simpson KJ, Porter BR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670484>
29. **Teleconsultation: Not every video provider is allowed!** *MMW-Fortschritte der Medizin* 2020; 162:30Zimmermann GW.



30. **Patient Perceptions of Head and Neck Ambulatory Telemedicine Visits: A Qualitative Study.** *Otolaryngol Head Neck Surg* 2020;194599820943523Triantafyllou V, Layfield E, Prasad A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662749>
31. **computer modelling of a potential agent against SARS-Cov-2 (COVID-19) protease.** *Proteins* 2020; Lesk AM, Konagurthu AS, Allison L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662915>
32. **"Soup cans, brooms, and Zoom:" Rapid conversion of a cancer survivorship program to telehealth during COVID-19.** *Psychooncology* 2020; Jhaveri K, Cohen JA, Barulich M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672845>
33. **Bridging the distance: continuing psycho-oncological care via video-consults during the COVID-19 pandemic.** *Psychooncology* 2020; van der Lee ML, Schellekens MPJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658316>
34. **The Potential for Remotely Mentored Patient-Performed Home Self-Monitoring for New Onset Alveolar-Interstitial Lung Disease.** *Telemed J E Health* 2020; Kirkpatrick AW, McKee JL, Volpicelli G, Ma IWY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654656>
35. **Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic.** *Telemed J E Health* 2020; Miele G, Straccia G, Moccia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667839>

## Other – Miscellaneous (43 articles)

1. **Is 2020 the year when primatologists should cancel fieldwork? A reply.** *Am. J. Primatol.* 2020:e23173Trivedy C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662075>
2. **Projected geographic disparities in healthcare worker absenteeism from COVID-19 school closures and the economic feasibility of child care subsidies: a simulation study.** *BMC Med* 2020; 18:218Chin ET, Huynh BQ, Lo NC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664927>
3. **Bin it or pin it? Which professional ethical guidance on managing COVID-19 should I follow?** *BMC Med. Ethics* 2020; 21:60Huxtable R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664908>
4. **Exposure to Nitrogen Dioxide (NO2) from Vehicular Emission Could Increase the COVID-19 Pandemic Fatality in India: A Perspective.** *Bull. Environ. Contam. Toxicol.* 2020; Chakraborty P, Jayachandran S, Padalkar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671411>
5. **The "Intubox": Enhancing Frontline Healthcare Worker Safety During Coronavirus Disease 2019 (COVID-19).** *Cureus* 2020; 12:e8530Motara F, Laher AE, Du Plessis J, Moolla M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665877>
6. **Environmental health workforce - essential for interdisciplinary solutions to the COVID-19 pandemic.** *Disaster Med Public Health Prep* 2020:1-7Ryan BJ, Swienton R, Harris C, James JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660683>
7. **Mitigating the twin threats of climate-driven Atlantic hurricanes and COVID-19 transmission.** *Disaster Med Public Health Prep* 2020:1-30Shultz JM, Kossin JP, Hertelendy AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660664>
8. **Effect of COVID-19 on Tuberculosis Notification, South Korea.** *Emerg Infect Dis* 2020; 26Kwak N, Hwang SS, Yim JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672531>
9. **Temporal association between particulate matter pollution and case fatality rate of COVID-19 in Wuhan.** *Environ. Res.* 2020; 189:109941Yao Y, Pan J, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678728>
10. **The mediating effect of air quality on the association between human mobility and COVID-19 infection in China.** *Environ. Res.* 2020; 189:109911Zhu Y, Xie J, Huang F, Cao L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678740>
11. **Expanding Possibilities: Flexibility and Solidarity with Under Resourced Immigrant Families During the Covid-19 Pandemic.** *Fam. Process* 2020; Falicov C, Nino A, D'Urso MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663315>
12. **A false promise of COVID-19 'big' health data? Health data integrity and the ethics and realities of Australia's health information management practice.** *Health Inf. Manag.* 2020:1833358320941190Robinson K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680440>
13. **Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: crosstalk among calorie restriction, autophagy and immune response.** *Immunol. Lett.* 2020; Hannan MA, Rahman MA, Rahman MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659267>
14. **Climatic factors influence the spread of COVID-19 in Russia.** *Int. J. Environ. Health Res.* 2020:1-16Pramanik M, Udmale P, Bisht P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672064>
15. **Air Quality during COVID-19 in Four Megacities: Lessons and Challenges for Public Health.** *Int J Environ Res Public Health* 2020; 17Connerton P, Vicente de Assuncao J, Maura de Miranda R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674410>
16. **Statistical Forecast of Pollution Episodes in Macao during National Holiday and COVID-19.** *Int J Environ Res Public Health* 2020; 17Lei MT, Monjardino J, Mendes L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679925>
17. **How Does a Public Health Emergency Motivate People's Impulsive Consumption? An Empirical Study during the COVID-19 Outbreak in China.** *Int J Environ Res Public Health* 2020; 17Li M, Zhao T, Huang E, Li J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668635>
18. **Forecasting Covid-19 Dynamics in Brazil: A Data Driven Approach.** *Int J Environ Res Public Health* 2020; 17Pereira IG, Guerin JM, Silva Junior AG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679861>
19. **Are Populist Leaders Creating the Conditions for the Spread of COVID-19? Comment on "A Scoping Review of Populist Radical Right Parties' Influence on Welfare Policy and its Implications for Population Health in Europe".** *Int J Health Policy Manag* 2020; McKee M, Gugushvili A, Koltai J, Stuckler D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668893>
20. **Economic implications of decreased elective orthopaedic and musculoskeletal surgery volume during the coronavirus disease 2019 pandemic.** *Int. Orthop.* 2020; Best MJ, Aziz KT, McFarland EG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681371>
21. **COVID-19, Racism, and Racial Disparities in Kidney Disease: Galvanizing the Kidney Community Response.** *J Am Soc Nephrol* 2020; Crews DC, Purnell TS. <http://www.ncbi.nlm.nih.gov/pubmed/?>

- term=32660968
22. **Life Goes On.** *J. Bioeth. Inq.* 2020; Ashby MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661740>
  23. **A Statement of Solidarity on COVID-19 Pandemic 2020 by the South Asian Family Physicians.** *J Family Med Prim Care* 2020; 9:1795-1797 Kumar R, Naseem S, Jayatissa J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670919>
  24. **Information and Misinformation on COVID-19: a Cross-Sectional Survey Study.** *J Korean Med Sci* 2020; 35:e256 Gupta L, Gasparyan AY, Misra DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657090>
  25. **Economic interventions to ameliorate the impact of COVID-19 on the economy and health: an international comparison.** *J Public Health (Oxf)* 2020; Danielli S, Patria R, Donnelly P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657341>
  26. **Value-based medicine, a compass to guide health care decisions in the COVID-19 aftermath.** *Liver Int* 2020; Strazzabosco M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677111>
  27. **[Collateral damage of COVID-19 pandemic in private healthcare centres of Argentina].** *Medicina (B. Aires)* 2020; 80 Suppl 3:37-41 Bozovich GE, Alves De Lima A, Fosco M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658846>
  28. **AIDS 2020 file: "Staying healthy with HIV".** *Editorial. MMW-Fortschritte der Medizin* 2020; 162:5-6 Bogner JR, Esser S, Hollstein T *et al.*
  29. **Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics.** *mSphere* 2020; 5 Evans NG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669462>
  30. **In Memoriam: A Memoir for Our Fallen "Heroes".** *Neurosurgery* 2020; Chaurasia B, Deora H, El-Ghandour NMF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657330>
  31. **Dietary recommendations during the COVID-19 pandemic.** *Nutr. Rev.* 2020; de Faria Coelho-Ravagnani C, Corgosinho FC, Sanches FFZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653930>
  32. **Importance of the One Health approach to study the SARS-CoV-2 in Latin America.** *One Health* 2020; 10:100147 Bonilla-Aldana DK, Holguin-Rivera Y, Perez-Vargas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665970>
  33. **Overlapping of locust swarms with COVID-19 pandemic: a cascading disaster for Africa.** *Pathog Glob Health* 2020; 1-2 Rahaman MM, Saha O, Rakhi NN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662750>
  34. *Public Health Forum* 2020; 28:89 Redaktion D.
  35. **Exposure to bushfire and biomass smoke and the risk of bacterial and viral lung infection.** *Respirology* 2020; Shukla SD, O'Toole RF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662120>
  36. **Do the Benefits of COVID-19 Policies Exceed the Costs? Exploring Uncertainties in the Age-VSL Relationship.** *Risk Anal.* 2020; Robinson LA, Sullivan R, Shogren JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677076>
  37. **Impact of quarantine measures on chemical compositions of PM2.5 during the COVID-19 epidemic in Shanghai, China.** *Sci Total Environ* 2020; 743:140758 Chen H, Huo J, Fu Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653718>
  38. **Levels and sources of hourly PM2.5-related elements during the control period of the COVID-19 pandemic at a rural site between Beijing and Tianjin.** *Sci Total Environ* 2020; 744:140840 Cui Y, Ji D, Maenhaut W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674021>
  39. **SARS-CoV-2 in river water: Implications in low sanitation countries.** *Sci Total Environ* 2020; 743:140832 Guerrero-Latorre L, Ballesteros I, Villacres-Granda I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679506>
  40. **Repercussions of COVID-19 pandemic on municipal solid waste management: Challenges and opportunities.** *Sci Total Environ* 2020; 743:140693 Kulkarni BN, Anantharama V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663690>
  41. **Meteorological impact on the COVID-19 pandemic: A study across eight severely affected regions in South America.** *Sci Total Environ* 2020; 744:140881 Zhu L, Liu X, Huang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674022>
  42. **Global Challenges of Being a Strength Athlete during a Pandemic: Impacts and Sports-Specific Training Considerations and Recommendations.** *Sports (Basel)* 2020; 8 Latella C, Haff GG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674388>
  43. **First expert elicitation of knowledge on drivers of emergence of the COVID-19 in pets.** *Transbound Emerg Dis* 2020; Saegerman C, Bianchini J, Renault V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654387>

## Pathology (10 articles)

1. **The autopsy at the time of SARS-CoV-2: Protocol and lessons.** *Ann. Diagn. Pathol.* 2020; 48:151562 Carpenito L, D'Ercole M, Porta F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653819>
2. **Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx.** *Ann. Diagn. Pathol.* 2020; 48:151565 Nuovo GJ, Magro C, Mikhail A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659620>
3. **Interventional cytopathology in COVID-19 ERA.** *Cytopathology* 2020; Ronchi A, Pagliuca F, Zito Marino F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654199>
4. **Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19.** *J Am Soc Nephrol* 2020; Golmai P, Larsen CP, DeVita MV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675304>
5. **Kidney Biopsy Findings in Patients with COVID-19.** *J Am Soc Nephrol* 2020; Kudose S, Batal I, Santoriello D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680910>
6. **Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series.** *J Crit Care* 2020; 59:149-155 Flikweert AW, Grootenboers M, Yick DCY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674001>
7. **Review: The safe handling of a corpse (suspected) with COVID-19.** *J. Forensic Leg. Med.* 2020; 73:101999 Dijkhuizen LGM, Gelderman HT, Duijst W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658757>
8. **Precautions in postmortem examinations in Covid-19 - Related deaths: Recommendations from Germany.** *J. Forensic Leg. Med.* 2020; 73:102000 Keten D, Okdemir E, Keten A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658758>

9. **Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations.** *Liver Int* 2020; Sonzogni A, Previtali G, Seghezzi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654359>
10. **Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison).** *Vet. Pathol.* 2020:300985820943535Molenaar RJ, Vreman S, Hakze-van der Honing RW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663073>

## Protection (41 articles)

1. **Risk to health from COVID-19 for anaesthetists and intensivists - a narrative review.** *Anaesthesia* 2020; Cook TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677708>
2. **[Specific characteristics of cardiopulmonary resuscitation in times of SARS-CoV-2].** *Anaesthesist* 2020; Hoechter DJ, Groene P, Hoffmann F, Kreimeier U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671430>
3. **Personal Protective Equipment and Evidence-Based Advice for Surgical Departments during COVID-19.** *ANZ J Surg* 2020; Tan L, Kovoov JG, Williamson P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671968>
4. **Personal protective equipment, airway management, and systematic reviews. Comment on Br J Anaesth (2020)[Epub ahead of print].** *Br J Anaesth* 2020; Sorbello M, El-Boghdady K, Schumacher J, Ahmad I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654744>
5. **Coronavirus antibody positive tests and continued use of personal protective equipment throughout the pandemic.** *Br. J. Oral Maxillofac. Surg.* 2020; Herron JBT, Dennis J, Brennan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660877>
6. **Laboratory work safety rules and guidelines during COVID-19 pandemic in Polish clinical laboratories - do our laboratories work according to a recent IFCC Taskforce Recommendations?** *Clin Chem Lab Med* 2020; Malecka M, Ogradzinska K, Salczynska G, Ciepiela O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673282>
7. **Comparing dynamics and determinants of SARS-CoV-2 transmissions among health care workers of adult and pediatric settings in central Paris.** *Clin Infect Dis* 2020; Contejean A, Leporrier J, Canoui E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663849>
8. **Through a Face Mask.** *Clin. J. Oncol. Nurs.* 2020; 24:345Carr E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678363>
9. **Availability of Personal Protective Equipment (PPE) Among US and Pakistani Doctors in COVID-19 Pandemic.** *Cureus* 2020; 12:e8550Ahmed J, Malik F, Bin Arif T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670687>
10. **SARS-CoV-2/COVID-19: systematic review of requirements for personal protective equipment in primary patient contact and organization of the operating area.** *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin* 2020; 91:576-585Schnitzbauer AA, Kempf VAJ, Hack D *et al.*
11. **Seroprevalence and SARS-CoV-2 testing in healthcare occupations.** *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft* 2020; Ziemssen F, Bayyoud T, Bartz-Schmidt KU *et al.*
12. **Effectiveness and recommendations for the use of dental masks in the prevention of COVID-19: A literature review.** *Disaster Med Public Health Prep* 2020:1-20Arellano-Cotrino JJ, Marengo-Coronel N, Atoche-Socola KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674741>
13. **COVID-19 Contact tracing solutions for mass gatherings.** *Disaster Med Public Health Prep* 2020:1-16Ryan BJ, Coppola D, Williams J, Swienton R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660677>
14. **Rapid inactivation of SARS-CoV-2 with Deep-UV LED irradiation.** *Emerg Microbes Infect* 2020:1-8Inagaki H, Saito A, Sugiyama H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673522>
15. **First data analysis about possible COVID-19 virus airborne diffusion due to air particulate matter (PM): The case of Lombardy (Italy).** *Environ. Res.* 2020; 186:109639Bontempi E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668559>
16. **Transmission of droplet-conveyed infectious agents such as SARS-CoV-2 by speech and vocal exercises during speech therapy: preliminary experiment concerning airflow velocity.** *Eur Arch Otorhinolaryngol* 2020; Giovanni A, Radulesco T, Bouchet G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676677>
17. **COVID-19: in the absence of vaccination - 'mask-the-nation'.** *Future Microbiol.* 2020; R DS, Darby S, Giltinan A, Smith N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677846>
18. **Perceived Threat of COVID-19 Contagion and Frontline Paramedics' Agonistic Behaviour: Employing a Stressor-Strain-Outcome Perspective.** *Int J Environ Res Public Health* 2020; 17Shahzad F, Du J, Khan I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679748>
19. **Were protective procedures against SARS-CoV-2 effective in an orthopaedic and trauma centre during the lockdown period? A retrospective study.** *Int. Orthop.* 2020; Bouche PA, Valteau B, Dumaine V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676776>
20. **Allowing Visitors Back in the Nursing Home During the COVID-19 Crisis: A Dutch National Study Into First Experiences and Impact on Well-Being.** *J. Am. Med. Dir. Assoc.* 2020; 21:900-904Verbeek H, Gerritsen DL, Backhaus R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674816>
21. **Opportunities for Biomaterials to Address the Challenges of COVID-19.** *J. Biomed. Mater. Res. A* 2020; Chakhalian D, Shultz RB, Miles C, Kohn J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662571>
22. **Safe percutaneous dilational tracheostomy in 5 patients with ARDS by Covid-19.** *J. Clin. Anesth.* 2020; 67:109977Taboada M, Vazquez S, Regueira J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653759>
23. **Rules and guidelines on distancing in daily life for the control of COVID-19 in Korea 3rd version announced on July 3, 2020.** *J Educ Eval Health Prof* 2020; 17:20. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663925>
24. **Review: The safe handling of a corpse (suspected) with COVID-19.** *J. Forensic Leg. Med.* 2020; 73:101999Dijkhuizen LGM, Gelderman HT, Duijst W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658757>
25. **Precautions in postmortem examinations in Covid-19 - Related deaths: Recommendations from Germany.** *J. Forensic Leg. Med.* 2020; 73:102000Keten D, Okdemir E, Keten A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658758>



26. **[Masks as personal protective equipment in the COVID-19 pandemic: How, when and which should be used].** *J Healthc Qual Res* 2020; Aranaz Andres JM, Gea Velazquez de Castro MT, Vicente-Guijarro J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680724>
27. **DECONTAMINATION INTERVENTIONS FOR THE REUSE OF SURGICAL MASK PERSONAL PROTECTIVE EQUIPMENT: A SYSTEMATIC REVIEW.** *J Hosp Infect* 2020; Zorko DJ, Gertsman S, O'Hearn K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653432>
28. **Personal Protective Equipment during the COVID-19 pandemic and operative time in cesarean section: retrospective cohort study.** *J Matern Fetal Neonatal Med* 2020:1-4Cuerva MJ, Carbonell M, Martin Palumbo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662314>
29. **Absence of in-flight transmission of SARS-CoV-2 likely due to use of face masks on board.** *J Travel Med* 2020; Nir-Paz R, Grotto I, Strolov I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662832>
30. **Natural protection of ocular surface from viral infections - A hypothesis.** *Med. Hypotheses* 2020; 143:110082Zimmerman K, Kearns F, Tzekov R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679424>
31. **Risks of aerosol drug therapy in COVID-19: much ado about nothing?** *Notfall und Rettungsmedizin* 2020; Clemens J.
32. **Face Mask-Associated Ocular Irritation and Dryness.** *Ophthalmol Ther* 2020; Moshirfar M, West WB, Jr., Marx DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671665>
33. **Efficacy of Povidone-Iodine to Reduce Viral Load.** *Oral Dis* 2020; Cimolai N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677126>
34. **COVID-19 Airway Management Isolation Chamber.** *Otolaryngol Head Neck Surg* 2020:194599820942500Blood TC, Jr., Perkins JN, Wistermayer PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662735>
35. **Aerosol Dispersion During Mastoidectomy and Custom Mitigation Strategies for Otologic Surgery in the COVID-19 Era.** *Otolaryngol Head Neck Surg* 2020:194599820941835Chari DA, Workman AD, Chen JX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660367>
36. **High-Efficiency Particulate Air Filters in the Era of COVID-19: Function and Efficacy.** *Otolaryngol Head Neck Surg* 2020:194599820941838Christopherson DA, Yao WC, Lu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662746>
37. **Evaluation of the spatter-reduction effectiveness and aerosol containment of eight dry-field isolation techniques.** *Quintessence Int.* 2020:2-12Ravenel TD, Kessler R, Comisi JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661521>
38. **[Nasopharyngeal carriage of SARS-CoV-2 among health personnel with symptoms suggestive of COVID-19 in a University Hospital in the Paris suburbs].** *Rev. Med. Interne* 2020; Greffe S, Espinasse F, Duran C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680715>
39. **Inanimate surfaces as potential source of 2019-nCoV spread and their disinfection with biocidal agents.** *Virusdisease* 2020; 31:94-96Akram MZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656305>
40. **Relevance of SARS-CoV-2 in food safety and food hygiene: potential preventive measures, suggestions and nanotechnological approaches.** *Virusdisease* 2020; 31:154-160Ceylan Z, Meral R, Cetinkaya T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656309>
41. **COVID-19: Knowledge, risk perception and strategies for handling the pandemic.** *Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen* 2020; Führer A, Frese T, Karch A *et al.*

## Pulmonary disease (17 articles)

1. **SARS-CoV-2 (COVID-19) and Cystic Fibrosis.** *Am J Physiol Lung Cell Mol Physiol* 2020; Stanton BA, Hampton TH, Ashare A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668165>
2. **Detection of Invasive Pulmonary Aspergillosis in COVID-19 with Non-directed Bronchoalveolar Lavage.** *Am J Respir Crit Care Med* 2020; Van Biesen S, Kwa D, Bosman RJ, Juffermans NP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668167>
3. **CovXNet: A multi-dilation convolutional neural network for automatic COVID-19 and other pneumonia detection from chest X-ray images with transferable multi-receptive feature optimization.** *Comput. Biol. Med.* 2020; 122:103869Mahmud T, Rahman MA, Fattah SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658740>
4. **The COVID-19 Pandemic Confronts the Motivation Fallacy within Pulmonary Rehabilitation Programs.** *Copd* 2020:1-3Karloh M, Sousa Matias T, Fleig Mayer A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657171>
5. **COVID-19 associated pneumonia despite repeatedly negative PCR-analysis from oropharyngeal swabs.** *Deutsche Medizinische Wochenschrift* 2020; 145:844-849Hornuss D, Laubner K, Monasterio C *et al.*
6. **Radiographic and chest CT imaging presentation and follow-up of COVID-19 pneumonia: a multicenter experience from an endemic area.** *Emerg Radiol* 2020; Vernuccio F, Giambelluca D, Cannella R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653961>
7. **COVID-19, Chronic Obstructive Pulmonary Disease and Pneumothorax: A Frightening Triad.** *Eur J Case Rep Intern Med* 2020; 7:001742Poggiali E, Vercelli A, Iannicelli T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665932>
8. **Unusually Rapid Development of Pulmonary Hypertension and Right Ventricular Failure after COVID-19 Pneumonia.** *Eur J Case Rep Intern Med* 2020; 7:001784van Dongen CM, Janssen MT, van der Horst RP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665939>
9. **Coronavirus Disease-19 Pneumonia with Facial Nerve Palsy and Olfactory Disturbance.** *Intern Med* 2020; 59:1773-1775Homma Y, Watanabe M, Inoue K, Moritaka T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669517>
10. **Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.** *J Am Soc Nephrol* 2020; Wysocki J, Lores E, Ye M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669323>
11. **Management of crash and burn patients with SARS-CoV-2 associated ARDS.** *J. Card. Surg.* 2020; Ghodsizad A, Grant AA, Mirsaeidi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663349>
12. **COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?** *Neuroscientist* 2020:1073858420939033Oliviero A, de Castro F, Coperchini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659199>

13. **Thromboinflammation in COVID-19 acute lung injury.** *Paediatr. Respir. Rev.* 2020; Mitchell WB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653469>
14. **Asthma prevalence in patients with SARS-CoV-2 infection detected by RT-PCR not requiring hospitalization.** *Respir. Med.* 2020; 171:106084 Garcia-Pachon E, Zamora-Molina L, Soler-Sempere MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658837>
15. **The Potential for Remotely Mentored Patient-Performed Home Self-Monitoring for New Onset Alveolar-Interstitial Lung Disease.** *Telemed J E Health* 2020; Kirkpatrick AW, McKee JL, Volpicelli G, Ma IWY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654656>
16. **Low Rate of COVID-19 pneumonia in Kidney Transplant Recipients - A Battle Between Infection and Immune Response?** *Transpl Infect Dis* 2020:e13406 Ghaffari Rahbar M, Nafar M, Khoshdel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654357>
17. **[Extra-pulmonary clinical manifestations of novel coronavirus pneumonia].** *Zhonghua Gan Zang Bing Za Zhi* 2020; 28:528-531 Li H, Hu P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660186>

## Renal disease (18 articles)

1. **COVID-19 Outbreak in an Urban Hemodialysis Unit.** *Am J Kidney Dis* 2020; Yau K, Muller MP, Lin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681983>
2. **COVID-19 Outbreak and Management Approach for Families with Children on Long-Term Kidney Replacement Therapy.** *Clin J Am Soc Nephrol* 2020; Zhao R, Zhou Q, Wang XW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665227>
3. **Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis.** *Crit Care* 2020; 24:439 Chen YT, Shao SC, Lai EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677972>
4. **Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.** *ESMO Open* 2020; 5:Aepli S, Eboulet EI, Eisen T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669298>
5. **Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic.** *Infect Dis (Lond)* 2020:1-8 Oltean M, Softeland JM, Bagge J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657186>
6. **COVID-19, Racism, and Racial Disparities in Kidney Disease: Galvanizing the Kidney Community Response.** *J Am Soc Nephrol* 2020; Crews DC, Purnell TS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660968>
7. **AKI in Hospitalized Patients with and without COVID-19: A Comparison Study.** *J Am Soc Nephrol* 2020; Fisher M, Neugarten J, Bellin E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669322>
8. **Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19.** *J Am Soc Nephrol* 2020; Golmai P, Larsen CP, DeVita MV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675304>
9. **Kidney Biopsy Findings in Patients with COVID-19.** *J Am Soc Nephrol* 2020; Kudose S, Batal I, Santoriello D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680910>
10. **COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings.** *J Am Soc Nephrol* 2020; Sharma P, Uppal NN, Wanchoo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660970>
11. **Rationing Scarce Resources: The Potential Impact of COVID-19 on Patients with Chronic Kidney Disease.** *J Am Soc Nephrol* 2020; Silberzweig J, Ikizler TA, Kramer H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669321>
12. **Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.** *J Am Soc Nephrol* 2020; Wysocki J, Lores E, Ye M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669323>
13. **COVID-19 and the kidneys.** *Nephrologie* 2020; 15:210-215 Rohn H, Feldkamp T, Witzke O.
14. **COVID-19 and Kidney Transplant Recipients.** *Transpl Infect Dis* 2020:e13413 Abolghasemi S, Mardani M, Sali S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677721>
15. **Kidney Transplantation during Coronavirus 2019 Pandemic at a Large Hospital in Miami.** *Transpl Infect Dis* 2020:e13416 Chandorkar A, Coro A, Natori Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681708>
16. **COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul.** *Transpl Infect Dis* 2020:e13371 Demir E, Uyar M, Parmaksiz E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657540>
17. **Low Rate of COVID-19 pneumonia in Kidney Transplant Recipients - A Battle Between Infection and Immune Response?** *Transpl Infect Dis* 2020:e13406 Ghaffari Rahbar M, Nafar M, Khoshdel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654357>
18. **Clinical Characteristics and Outcome of Covid-19 Pneumonia in kidney Transplant Recipients in Razi hospital, Rasht, Iran.** *Transpl Infect Dis* 2020:e13420 Monfared A, Dashti-Khavidaki S, Jafari R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681756>

## Reviews (58 articles)

1. **A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19.** *Acta Obstet Gynecol Scand* 2020; D'Souza R, Malhame I, Teshler L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678949>
2. **Lung ultrasound in the diagnosis of COVID-19 infection - A case series and review of the literature.** *Adv. Med. Sci.* 2020; 65:378-385 Buda N, Segura-Grau E, Cylwik J, Welnicki M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659729>
3. **Prevalence of Comorbidities Among Individuals With COVID-19: A Rapid Review of current Literature.** *Am. J. Infect. Control* 2020; Bajgain KT, Badal S, Bajgain BB, Santana MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659414>
4. **Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19.** *Am. J. Infect. Control* 2020; Boger B, Fachi MM, Vilhena RO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659413>

5. **Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era.** *Am. J. Med.* 2020; Massoomi MR, Anderson RD, Ahmed MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653420>
6. **Risk to health from COVID-19 for anaesthetists and intensivists - a narrative review.** *Anaesthesia* 2020; Cook TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677708>
7. **2019 NOVEL CORONAVIRUS.** *Ann Ib Postgrad Med* 2019; 17:108-110 Fagbule OF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669985>
8. **COVID-19 and the quality use of medicines: evidence, risks and fads.** *Aust Prescr* 2020; 43:78-80 Roberts DM, Bennett A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675907>
9. **Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.** *BJGP Open* 2020; Dambha-Miller H, Albasri A, Hodgson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665234>
10. **Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.** *BMC Med* 2020; 18:215 Ostuzzi G, Papola D, Gastaldon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664944>
11. **Personal protective equipment, airway management, and systematic reviews. Comment on Br J Anaesth (2020)[Epub ahead of print].** *Br J Anaesth* 2020; Sorbello M, El-Boghdady K, Schumacher J, Ahmad I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654744>
12. **Safety perspectives on presently considered drugs for the treatment of COVID-19.** *Br. J. Pharmacol.* 2020; Penman SL, Kiy RT, Jensen RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681537>
13. **The recent challenges of highly contagious COVID-19; causing respiratory infections: symptoms, diagnosis, transmission, possible vaccines, animal models and immunotherapy.** *Chem. Biol. Drug Des.* 2020; Mohapatra RK, Pintilie L, Kandi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654267>
14. **From H1N1 to 2019-nCoV, what do we learn?** *Chin. J. Traumatol.* 2020; Liu GE, Tian Y, Zhao WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669221>
15. **Hospitalized COVID-19 Patients and Venous Thromboembolism: A Perfect Storm.** *Circulation* 2020; 142:129-132 Spyropoulos AC, Weitz JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658609>
16. **SARS-CoV-2 and the cardiovascular system.** *Clin Chim Acta* 2020; Hafiane A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681935>
17. **COVID-19: review and hematologic impact.** *Clin Chim Acta* 2020; Leticia de Oliveira Toledo S, Sousa Nogueira L, das Gracas Carvalho M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659224>
18. **Neurological manifestations of COVID-19: a systematic review.** *Crit Care* 2020; 24:421 Nepal G, Rehrig JH, Shrestha GS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660520>
19. **Atypical Neurological Manifestations of COVID-19.** *Cureus* 2020; 12:e8518 Gupta I, Reddy MK, Hussain MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656033>
20. **Clinical Perspective on 2019 Novel Coronavirus Pneumonia: A Systematic Review of Published Case Reports.** *Cureus* 2020; 12:e8488 Patel RS, Patel N, Baksh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656006>
21. **SARS-CoV-2/COVID-19: systematic review of requirements for personal protective equipment in primary patient contact and organization of the operating area.** *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen* 2020; 91:576-585 Schnitzbauer AA, Kempf VAJ, Hack D *et al.*
22. **Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review.** *Diabetes Metab Syndr* 2020; 14:1133-1142 Zaki N, Alashwal H, Ibrahim S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663789>
23. **Effectiveness and recommendations for the use of dental masks in the prevention of COVID-19: A literature review.** *Disaster Med Public Health Prep* 2020:1-20 Arellano-Cotrino JJ, Marengo-Coronel N, Atoche-Socola KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674741>
24. **Biosafety for dental patients during dentistry care after COVID-19: A review of the literature.** *Disaster Med Public Health Prep* 2020:1-17 Siles-Garcia AA, Alzamora-Cepeda AG, Atoche-Socola KJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660663>
25. **Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.** *Drugs Context* 2020; 9 Hon KL, Leung KKY, Leung AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655654>
26. **COVID-19 and ENT surgery: a brief review of essential precautions and triage.** *Eur Arch Otorhinolaryngol* 2020; Sharma A, Bhardwaj R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654024>
27. **Targeting the NLRP3 Inflammasome in Severe COVID-19.** *Front. Immunol.* 2020; 11:1518 Freeman TL, Swartz TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655582>
28. **Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.** *Front. Immunol.* 2020; 11:1531 Konwarh R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655584>
29. **Chest Computed Tomography and Lung Ultrasound Findings in COVID-19 Pneumonia: A Pocket Review for Non-radiologists.** *Front Med (Lausanne)* 2020; 7:375 Pata D, Valentini P, De Rose C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671086>
30. **A Contemporary Review of Neurological Sequelae of COVID-19.** *Front. Neurol.* 2020; 11:640 Fiani B, Covarrubias C, Desai A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655489>
31. **Coronaviruses and Central Nervous System Manifestations.** *Front. Neurol.* 2020; 11:715 Khateb M, Bosak N, Muqary M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655490>
32. **Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.** *Fundam. Clin. Pharmacol.* 2020; Parlakpınar H, Polat S, Acet HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657483>
33. **Coronavirus Disease 2019: A Gastroenterologist's Perspective in May 2020.** *Gastroenterology Res* 2020; 13:89-95 Ahmed M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655724>
34. **COVID-19 and Spine Surgery: A Review and Evolving Recommendations.** *Global Spine J* 2020; 10:528-533 Jain NS, Alluri RK, Schopler SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677557>
35. **Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic.** *Infect Dis (Lond)* 2020:1-8 Oltean M, Softeland JM, Bagge J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657186>
36. **Clinical Presentation of COVID-19: Case Series and Review of the Literature.** *Int J Environ Res Public Health* 2020; 17:Macera M, De Angelis G, Sagnelli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674450>
37. **Are Populist Leaders Creating the Conditions for the Spread of COVID-19? Comment on "A Scoping Review of Populist Radical Right Parties' Influence on Welfare Policy and its Implications for**



- Population Health in Europe".** *Int J Health Policy Manag* 2020; McKee M, Gugushvili A, Koltai J, Stuckler D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668893>
38. **COVID-19: review of case reports.** *J. Anesth.* 2020; Oda Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656688>
  39. **COVID-19: A Review for the Pediatric Neurologist.** *J. Child Neurol.* 2020;883073820939387Christy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660309>
  40. **The Impact of COVID-19 Global Pandemic on Morbidity and Mortality of Liver Transplant Recipients Children and Adults: A Systematic Review of Case Series.** *J. Clin. Med. Res.* 2020; 12:404-408Gavriilidis P, Pai M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655733>
  41. **Novel coronavirus: A capsule review for primary care and acute care physicians.** *J Family Med Prim Care* 2020; 9:1820-1824Sahu AK, Nayer J, Aggarwal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670925>
  42. **Current perspective on pandemic of COVID-19 in the United States.** *J Family Med Prim Care* 2020; 9:1784-1791Sahu KK, Kumar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670917>
  43. **DECONTAMINATION INTERVENTIONS FOR THE REUSE OF SURGICAL MASK PERSONAL PROTECTIVE EQUIPMENT: A SYSTEMATIC REVIEW.** *J Hosp Infect* 2020; Zorko DJ, Gertsman S, O'Hearn K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653432>
  44. **Correlations between COVID-19 and burden of dementia: An ecological study and review of literature.** *J Neurol Sci* 2020; 416:117013Azarpazhooh MR, Amiri A, Morovatdar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659508>
  45. **Discordance of COVID-19 guidelines for patients with cancer: A systematic review.** *J. Surg. Oncol.* 2020; Garg PK, Kaul P, Choudhary D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668034>
  46. **COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature.** *J. Thromb. Thrombolysis* 2020; Tan YK, Goh C, Leow AST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661757>
  47. **Children in Coronaviruses' Wonderland: What Clinicians Need to Know.** *Mediterr. J. Hematol. Infect. Dis.* 2020; 12:e2020042Lassandro G, Palladino V, Amoroso A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670520>
  48. **Cardiovascular Implications of COVID-19 Infections.** *Methodist Debaquey Cardiovasc. J.* 2020; 16:146-154Thakkar AN, Tea I, Al-Mallah MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670475>
  49. **COVID-19 and the kidneys.** *Nephrologie* 2020; 15:210-215Rohn H, Feldkamp T, Witzke O.
  50. **Neurological manifestations of SARS-CoV-2 - a systemic review.** *Neurol. Neurochir. Pol.* 2020; Slyk S, Domitrz I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667047>
  51. **Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review.** *Otolaryngol Head Neck Surg* 2020:194599820933170Higgins TS, Wu AW, Illing EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660339>
  52. **Vaccines for COVID-19: The current state of play.** *Paediatr. Respir. Rev.* 2020; Koirala A, Joo YJ, Khatami A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653463>
  53. **Lessons learned from the mechanisms of posttraumatic inflammation extrapolated to the inflammatory response in COVID-19: a review.** *Patient Saf Surg* 2020; 14:28Teuben MPJ, Pfeifer R, Teuber H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665786>
  54. **COVID-19 and diabetes: What does the clinician need to know?** *Prim. Care Diabetes* 2020; Papadokostaki E, Tentolouris N, Liberopoulos E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654982>
  55. **Trends in clinical features of novel coronavirus disease (COVID-19): A systematic review and meta-analysis of studies published from December 2019 to February 2020.** *Respir Investig* 2020; Manabe T, Akatsu H, Kotani K, Kudo K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653383>
  56. **Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.** *Ther. Clin. Risk Manag.* 2020; 16:595-605Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669846>
  57. **Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.** *Vaccine* 2020; Osama El-Gendy A, Saeed H, Ali AMA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654907>
  58. **[Novel coronavirus infection (COVID-19) and nervous system involvement: pathogenesis, clinical manifestations, organization of neurological care].** *Zh. Nevrol. Psikiatr. Im. S. S. Korsakova* 2020; 120:7-16Gusev EI, Martynov MY, Boyko AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678542>

## Risk factors (55 articles)

1. **Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis.** *Aging (Albany NY)* 2020; 12Fang X, Li S, Yu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658868>
2. **SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity.** *Am J Clin Pathol* 2020; Phipps WS, SoRelle JA, Li QZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666092>
3. **Linkages Between Air Pollution and the Health Burden from COVID-19: Methodological Challenges and Opportunities.** *Am. J. Epidemiol.* 2020; Benmarhnia T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676643>
4. **The Relationship between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China.** *Am. J. Med.* 2020; Shang J, Wang Q, Zhang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653423>
5. **No added value of the modified NEWS score to predict clinical deterioration in COVID-19 patients.** *Anaesth Crit Care Pain Med* 2020; Volff M, Tonon D, Bourenne J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659455>
6. **Blood type and outcomes in patients with COVID-19.** *Ann. Hematol.* 2020; Latz CA, DeCarlo C, Boitano L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656591>
7. **Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.** *Antiviral Res* 2020:104880Gallian P, Pastorino B, Morel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679056>
8. **Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.** *BJGP Open* 2020; Dambha-Miller H, Albasri A, Hodgson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665234>

9. **New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.** *BMC Med* 2020; 18:216Hou Y, Zhao J, Martin W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664879>
10. **Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic.** *BMC Med* 2020; 18:220Kyrou I, Karteris E, Robbins T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664957>
11. **Exposure to Nitrogen Dioxide (NO2) from Vehicular Emission Could Increase the COVID-19 Pandemic Fatality in India: A Perspective.** *Bull. Environ. Contam. Toxicol.* 2020; Chakraborty P, Jayachandran S, Padalkar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671411>
12. **Serum prealbumin deserves more significance in the early triage of COVID-19 patients.** *Clin Chem Lab Med* 2020; Guo XL, Zhang Y, Zeng YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681771>
13. **Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection.** *Clin Chim Acta* 2020; Hu X, Chen D, Wu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653486>
14. **Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill COVID-19 patients.** *Clin Infect Dis* 2020; Dupont V, Kanagaratnam L, Goury A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672790>
15. **Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET).** *Clin Infect Dis* 2020; Kim L, Garg S, O'Halloran A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674114>
16. **Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity.** *Clin Infect Dis* 2020; Lynch KL, Whitman JD, Lacanienta NP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663256>
17. **Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.** *Crit Care* 2020; 24:422Ni W, Yang X, Yang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660650>
18. **Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study.** *Crit Care* 2020; 24:438Zhang S, Guo M, Duan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678040>
19. **SARS-CoV-2 (COVID 19) Infection in Hypertensive Patients and in Patients With Cardiac Disease.** *Cureus* 2020; 12:e8557Cancarevic I, Malik BH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670694>
20. **A Predictive Model for Patient Census and Ventilator Requirements at Individual Hospitals During the Coronavirus Disease 2019 (COVID-19) Pandemic: A Preliminary Technical Report.** *Cureus* 2020; 12:e8501Epstein RH, Dexter F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656017>
21. **BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank.** *Diabetes Metab Syndr* 2020; 14:1149-1151Sattar N, Ho FK, Gill JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668401>
22. **Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review.** *Diabetes Metab Syndr* 2020; 14:1133-1142Zaki N, Alashwal H, Ibrahim S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663789>
23. **Clinical features of fatalities in patients with COVID-19.** *Disaster Med Public Health Prep* 2020:1-10Sun YJ, Feng YJ, Chen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665052>
24. **Temporal association between particulate matter pollution and case fatality rate of COVID-19 in Wuhan.** *Environ. Res.* 2020; 189:109941Yao Y, Pan J, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678728>
25. **Systematic Review and Meta-Analysis of Sex-Specific COVID-19 Clinical Outcomes.** *Front Med (Lausanne)* 2020; 7:348Galbadage T, Peterson BM, Awada J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671082>
26. **Vitamin D Deficiency and Air Pollution Exacerbate COVID-19 Through Suppression of Antiviral Peptide LL37.** *Front Public Health* 2020; 8:232Crane-Godreau MA, Clem KJ, Payne P, Fiering S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671009>
27. **Vitamin D and COVID-19.** *Hormones (Athens)* 2020; Trovas G, Tournis S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666357>
28. **Effects of Renin-Angiotensin Inhibition on ACE2 and TMPRSS2 Expression: Insights into COVID-19.** *Hypertension* 2020; Wu C, Ye D, Mullick AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673509>
29. **The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity.** *Immunol. Rev.* 2020; Ovsyannikova IG, Haralambieva IH, Crooke SN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658335>
30. **COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?** *Int. J. Vitam. Nutr. Res.* 2020:1-2Alshahawey M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674673>
31. **Tobacco smoking cessation in mental health services during the COVID-19 pandemic.** *J. Addict. Dis.* 2020:1-3Seiler NK, Swamy R, Xiao J, Yun Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657671>
32. **Medical Vulnerability of Young Adults to Severe COVID-19 Illness-Data From the National Health Interview Survey.** *J. Adolesc. Health* 2020; Adams SH, Park MJ, Schaub JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674964>
33. **Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.** *J Am Soc Nephrol* 2020; Wysocki J, Lores E, Ye M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669323>
34. **The latitude hypothesis, vitamin D, and SARS-CoV-2.** *J Biomol Struct Dyn* 2020:1-3Hedlund R, Diamond TK, Uversky VN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677591>
35. **Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19.** *J. Clin. Lab. Anal.* 2020:e23467Chen X, Yan L, Fei Y, Zhang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656888>
36. **Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19.** *J. Clin. Med. Res.* 2020; 12:448-453Chan AS, Rout A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655740>
37. **Life-Threatening Psoas Hematoma due to Retroperitoneal Hemorrhage in a COVID-19 Patient on Enoxaparin Treated With Arterial Embolization: A Case Report.** *J. Clin. Med. Res.* 2020; 12:458-461Patel I, Akoluk A, Douedi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655742>
38. **Factors Leading to High Morbidity and Mortality of COVID-19 in Patients with Type 2 Diabetes.** *J. Diabetes* 2020; Rajpal A, Rahimi L, Ismail-Beigi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671936>

39. **Does temperature and humidity influence the spread of Covid-19?: A preliminary report.** *J Family Med Prim Care* 2020; 9:1811-1814 Raina SK, Kumar R, Bhota S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670923>
40. **Predictive Values of Blood Urea Nitrogen/Creatinine Ratio and Other Routine Blood Parameters on Disease Severity and Survival of COVID-19 Patients.** *J Med Virol* 2020; Ok F, Erdogan O, Durmus E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662893>
41. **COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness.** *J. Thromb. Thrombolysis* 2020; Du F, Liu B, Zhang S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676883>
42. **The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.** *Life Sci* 2020:118097 Abbasifard M, Khorramdelazad H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679148>
43. **The role of visceral adiposity in the severity of COVID-19: highlights from a unicenter cross-sectional pilot study in Germany.** *Metabolism* 2020:154317 Petersen A, Bressemer K, Albrecht J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673651>
44. **Commentary: COVID-19 and Obesity: Exploring Biologic Vulnerabilities, Structural Disparities, and Weight Stigma.** *Metabolism* 2020:154316 Townsend MJ, Kyle TK, Stanford FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673650>
45. **Awareness And Concerns About Novel Coronavirus Disease 2019 (COVID-19) Among Parents Of Pediatric Liver Transplant Recipients.** *Pediatr. Transplant.* 2020:e13805 Menon J, Shanmugam N, Patel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663351>
46. **Hemogram data as a tool for decision-making in COVID-19 management: applications to resource scarcity scenarios.** *PeerJ* 2020; 8:e9482 Avila E, Kahmann A, Alho C, Dorn M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656001>
47. **The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.** *Pharmacol Res Perspect* 2020; 8:e00623 Braga CL, Silva-Aguiar RP, Battaglini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658389>
48. **Risk factors for lethal clinical courses of COVID-19 in China.** *Pneumologie* 2020; 74:324-325 Klein F.
49. **High altitude reduces infection rate of COVID-19 but not case-fatality rate.** *Respir. Physiol. Neurobiol.* 2020:103494 Segovia-Juarez J, Castagnetto JM, Gonzales GF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679369>
50. **Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital.** *Rev Clin Esp* 2020; Martos Perez F, Luque Del Pino J, Jimenez Garcia N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680592>
51. **Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV.** *Rev Med Virol* 2020:e2144 Kadambari S, Klenerman P, Pollard AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671966>
52. **National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study.** *Scand. J. Trauma Resusc. Emerg. Med.* 2020; 28:66 Myrstad M, Ihle-Hansen H, Tveita AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660623>
53. **Are sex discordant outcomes in COVID-19 related to sex hormones?** *Semin. Oncol.* 2020; Strobe JD, Chau CH, Figg WD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660890>
54. **Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?** *Thromb Res* 2020; 195:74-76 Siguret V, Voicu S, Neuwirth M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663703>
55. **Understanding The Complex Relationship Between Androgens and SARS-CoV2.** *Urology* 2020; Ory J, Lima TFN, Towe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653566>

## Safety (18 articles)

1. **Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.** *Antiviral Res* 2020:104866 Venisse N, Peytavin G, Bouchet S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659293>
2. **COVID-19 and the quality use of medicines: evidence, risks and fads.** *Aust Prescr* 2020; 43:78-80 Roberts DM, Bennett A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675907>
3. **Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.** *BMC Med* 2020; 18:215 Ostuzzi G, Papola D, Gastaldon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664944>
4. **Safety perspectives on presently considered drugs for the treatment of COVID-19.** *Br. J. Pharmacol.* 2020; Penman SL, Kiy RT, Jensen RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681537>
5. **First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.** *Contact Dermatitis* 2020; Jimenez AC, Navarrate Navarrete N, Gratacos Gomez AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654163>
6. **Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.** *Heart Vessels* 2020; Moschini L, Loffi M, Regazzoni V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676695>
7. **Reply to letters vide manuscript ID IPEJ-D-20-00072, and IPEJ-D-20-00073 regarding our paper "Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.** *Indian Pacing Electrophysiol J* 2020; Kapoor A, Pandurangi U, Arora V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653526>
8. **Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?** *Int J Antimicrob Agents* 2020:106056 Machiels JD, Bleeker-Rovers CP, Ter Heine R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674929>
9. **Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?** *J Am Coll Cardiol* 2020; 76:277-279 Bloch MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674791>
10. **The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies.** *J Appl Physiol (1985)* 2020; Ferrandi PJ, Alway SE, Mohamed JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673162>



11. **QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.** *J. Interv. Card. Electrophysiol.* 2020; B CH, Greige N, J AQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654098>
12. **QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.** *J. Interv. Card. Electrophysiol.* 2020; Hsia BC, Greige N, Quiroz JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654098>
13. **Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.** *Life Sci.* 2020:118096 Hazra S, Chaudhuri AG, Tiwary BK, Chakrabarti N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679150>
14. **Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?** *Med. Hypotheses* 2020; 143:110018 Tastemur S, Ataseven H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679422>
15. **Risks of aerosol drug therapy in COVID-19: much ado about nothing?** *Notfall und Rettungsmedizin* 2020; Clemens J.
16. **Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.** *Pharmacol. Ther.* 2020:107628 Wang JJ, Edin ML, Zeldin DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653530>
17. **Technique, radiation safety and image quality for chest X-ray imaging through glass and in mobile settings during the COVID-19 pandemic.** *Phys Eng Sci Med* 2020; Brady Z, Scoullar H, Grinsted B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662037>
18. **Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.** *Ther. Clin. Risk Manag.* 2020; 16:595-605 Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669846>

## Treatment options (73 articles)

1. **BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?** *Allergol. Immunopathol. (Madr.)* 2020; Sharma AR, Batra G, Kumar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653224>
2. **Analysis of Traditional Chinese Medicine Diagnosis and Treatment Strategies for COVID-19 Based on "The Diagnosis and Treatment Program for Coronavirus Disease-2019" from Chinese Authority.** *Am J Chin Med* 2020; 48:1035-1049 Zhao ZH, Zhou Y, Li WH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668970>
3. **Immunoglobulin fragment F(ab')<sub>2</sub> against RBD potently neutralizes SARS-CoV-2 in vitro.** *Antiviral Res* 2020:104868 Pan X, Zhou P, Fan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659292>
4. **In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.** *Antiviral Res* 2020:104878 Pizzorno A, Padey B, Dubois J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679055>
5. **Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic.** *Aust Prescr* 2020; 43:76-77 Coombes I, Markwell A, Kubler P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675906>
6. **COVID-19 and the quality use of medicines: evidence, risks and fads.** *Aust Prescr* 2020; 43:78-80 Roberts DM, Bennett A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675907>
7. **Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.** *BJGP Open* 2020; Dambha-Miller H, Albasri A, Hodgson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665234>
8. **Safety perspectives on presently considered drugs for the treatment of COVID-19.** *Br. J. Pharmacol.* 2020; Penman SL, Kiy RT, Jensen RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681537>
9. **Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses.** *Brief. Bioinform.* 2020; Li R, Wu K, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662814>
10. **Longitudinal Isolation of Potent Near-Germ-line SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.** *Cell* 2020; Kreer C, Zehner M, Weber T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673567>
11. **Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.** *Cell Rep.* 2020:107940 Pruijssers AJ, George AS, Schafer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668216>
12. **Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.** *Cell Rep.* 2020:107918 Wan J, Xing S, Ding L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668215>
13. **Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.** *Chin J Integr Med* 2020; Wang JB, Wang ZX, Jing J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676976>
14. **Current strategies against COVID-19.** *Chin. Med.* 2020; 15:70 Hussain S, Xie YJ, Li D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665783>
15. **Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.** *Clin Infect Dis* 2020; Mitja O, Corbacho-Monne M, Ubals M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674126>
16. **First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.** *Contact Dermatitis* 2020; Jimenez AC, Navarrate Navarrete N, Gratacos Gomez AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654163>
17. **Clinical Perspective on 2019 Novel Coronavirus Pneumonia: A Systematic Review of Published Case Reports.** *Cureus* 2020; 12:e8488 Patel RS, Patel N, Baksh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656006>
18. **Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.** *Cureus* 2020; 12:e9038 Sheianov MV, Udalov YD, Ochkin SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656044>
19. **NPC1 as a Modulator of Disease Severity and Viral Entry of Sars-CoV-2.** *Curr. Mol. Med.* 2020; Vial C, Calderon JF, Klein AD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660402>
20. **Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?** *Curr Nutr Rep* 2020; Singh V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660402>

- term=32661859
21. **Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?** *Cytokine Growth Factor Rev.* 2020; Arico E, Bracci L, Castiello L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665127>
  22. **Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.** *Drug Discov Ther* 2020; 14:109-116 Marouf BH, Dizaye K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669519>
  23. **Traditional Chinese medicine to treat COVID-19: the importance of evidence-based research.** *Drug Discov Ther* 2020; 14:149-150 Wang J, Qi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669523>
  24. **Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.** *Drugs Context* 2020; 9 Hon KL, Leung KKY, Leung AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655654>
  25. **A Molecular Docking Study Repurposes FDA Approved Iron Oxide Nanoparticles to Treat and Control COVID-19 Infection.** *Eur. J. Pharm. Sci.* 2020:105465 Abo-Zeid Y, Ismail NS, McLean GR, Hamdy NM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32668312>
  26. **The Use of IV vitamin C for patients with COVID-19: a single center observational study.** *Expert Rev. Anti Infect. Ther.* 2020; Hiedra R, Lo KB, Elbashabsheh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662690>
  27. **Vitamin D Supplementation: A Potential Approach for Coronavirus/COVID-19 Therapeutics?** *Front. Immunol.* 2020; 11:1523 Arboleda JF, Urcuqui-Inchima S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655583>
  28. **Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.** *Front. Immunol.* 2020; 11:1439 Colafrancesco S, Scrivo R, Barbati C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655577>
  29. **Targeting the NLRP3 Inflammasome in Severe COVID-19.** *Front. Immunol.* 2020; 11:1518 Freeman TL, Swartz TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655582>
  30. **Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.** *Front. Immunol.* 2020; 11:1531 Konwarh R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655584>
  31. **Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.** *Front. Immunol.* 2020; 11:1512 Market M, Angka L, Martel AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655581>
  32. **Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?** *Front. Immunol.* 2020; 11:1102 Naz F, Arish M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670273>
  33. **Biocides and Novel Antimicrobial Agents for the Mitigation of Coronaviruses.** *Front. Microbiol.* 2020; 11:1351 Dev Kumar G, Mishra A, Dunn L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655532>
  34. **Pharmacotherapies Advice in Guidelines for COVID-19.** *Front. Pharmacol.* 2020; 11:950 Chen ZR, Zhou Y, Liu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670066>
  35. **Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy.** *Front. Pharmacol.* 2020; 11:966 Wang Y, Zhang Y, Yu Q, Zhu K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670071>
  36. **Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.** *Fundam. Clin. Pharmacol.* 2020; Parlakpinar H, Polat S, Acet HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657483>
  37. **Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.** *Future Med. Chem.* 2020; VanPatten S, He M, Altiti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672061>
  38. **N-acetylcysteine as a potential treatment for novel coronavirus disease 2019.** *Future Microbiol.* 2020; Jorge-Aaron RM, Rosa-Ester MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662664>
  39. **Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.** *Heart Vessels* 2020; Moschini L, Loffi M, Regazzoni V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676695>
  40. **An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.** *Hum Vaccin Immunother* 2020:1-6 Sheikhi A, Hojjat-Farsangi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663051>
  41. **Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.** *Immunotherapy* 2020; Cala-Garcia JD, Sierra-Breton JD, Cavellier-Baiz JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664810>
  42. **Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?** *Int J Antimicrob Agents* 2020:106056 Machiels JD, Bleeker-Rovers CP, Ter Heine R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674929>
  43. **Re: Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?** *Int. J. Radiat. Biol.* 2020:1-4 Bevelacqua JJ, Mortazavi S, Mortazavi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32673140>
  44. **Can Vitamin D and L-Cysteine Co-Supplementation Reduce 25(OH)-Vitamin D Deficiency and the Mortality Associated with COVID-19 in African Americans?** *J. Am. Coll. Nutr.* 2020:1-6 Jain SK, Parsanathan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659175>
  45. **The Effects of ARBs, ACEIs, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.** *J. Am. Med. Dir. Assoc.* 2020; 21:909-914.e902 De Spiegeleer A, Bronselaer A, Teo JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674818>
  46. **Ayurvedic treatment of COVID-19/SARS-CoV-2: A case report.** *J. Ayurveda Integr. Med.* 2020; Giriya PLT, Sivan N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32680602>
  47. **First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.** *J. Clin. Med. Res.* 2020; 12:454-457 Padala SA, Vakiti A, White JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32655741>
  48. **Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.** *J. Intensive Care Med.* 2020:885066620940259 Tabibi S, Tabibi T, Conic RRZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666875>
  49. **QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.** *J. Interv. Card. Electrophysiol.* 2020; B CH, Greige N, J AQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654098>

50. **QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.** *J. Interv. Card. Electrophysiol.* 2020; Hsia BC, Greige N, Quiroz JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654098>
51. **Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection.** *J Med Virol* 2020; Chandrasekar VT, Venkatesalu B, Patel HK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32667699>
52. **Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** *J Med Virol* 2020; Copertino DC, Duarte RRR, Powell TR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658304>
53. **Montelukast drug activity and potential against SARS-CoV-2.** *J Med Virol* 2020; Copertino DC, Jr., Duarte RRR, Powell TR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658304>
54. **Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study.** *J Med Virol* 2020; Fernandez-Ruiz M, Lopez-Medrano F, Asin MAP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32672860>
55. **Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.** *Life Sci* 2020; 257:118080Bharadwaj S, Lee KE, Dwivedi VD, Kang SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653520>
56. **Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.** *Life Sci* 2020:118096Hazra S, Chaudhuri AG, Tiwary BK, Chakrabarti N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32679150>
57. **Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment.** *Mar. Pollut. Bull.* 2020; 157:111375Essid N, Allouche M, Lazzem M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658716>
58. **Surfactant-based prophylaxis and therapy against COVID-19: A possibility.** *Med. Hypotheses* 2020; 143:110081Pramod K, Kotta S, Jijith US *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653736>
59. **Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.** *Medicina (B. Aires)* 2020; 80 Suppl 3:1-6Zylberman V, Sanguineti S, Pontoriero AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658841>
60. **Lopinavir-ritonavir for COVID-19: A living systematic review.** *Medwave* 2020; 20:e7967Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678815>
61. **Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19.** *Nitric Oxide* 2020; Adusumilli NC, Zhang D, Friedman JM, Friedman AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681986>
62. **Risks of aerosol drug therapy in COVID-19: much ado about nothing?** *Notfall und Rettungsmedizin* 2020; Clemens J.
63. **Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.** *Open Forum Infect Dis* 2020; 7:ofaa241Chen J, Xia L, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671131>
64. **Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review.** *Otolaryngol Head Neck Surg* 2020:194599820933170Higgins TS, Wu AW, Illing EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660339>
65. **The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.** *Pharmacol Res Perspect* 2020; 8:e00623Braga CL, Silva-Aguiar RP, Battaglini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32658389>
66. **Contribution of traditional Chinese medicine to the treatment of COVID-19.** *Phytomedicine* 2020:153279Wang WY, Xie Y, Zhou H, Liu L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32675044>
67. **Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.** *Respir Med Case Rep* 2020; 31:101115Sodani P, Mucci L, Girolimetti R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32670785>
68. **Can medicinal mushrooms have prophylactic or therapeutic effect against COVID-19 and its pneumonic superinfection and complicating inflammation?** *Scand. J. Immunol.* 2020:e12937Hetland G, Johnson E, Bernardshaw SV, Grinde B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657436>
69. **A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.** *Stem Cell. Res. Ther.* 2020; 11:291Peng H, Gong T, Huang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678017>
70. **The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:646Denholm JT, Davis J, Paterson D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665040>
71. **A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:639Smith K, Pace A, Ortiz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660611>
72. **Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.** *Vaccine* 2020; Osama El-Gendy A, Saeed H, Ali AMA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654907>
73. **Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor.** *Virusdisease* 2020; 31:179-193Maurya VK, Kumar S, Prasad AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656311>

## **Trials (12 articles)**

1. **Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.** *Chin J Integr Med* 2020; Wang JB, Wang ZX, Jing J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32676976>
2. **Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.** *Clin Infect Dis* 2020; Mitja O, Corbacho-Monne M, Ubals M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674126>



3. **Endpoints for randomized controlled clinical trials for COVID-19 treatments.** *Clin. Trials* 2020;1740774520939938Dodd LE, Follmann D, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674594>
4. **Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.** *Clin. Trials* 2020;1740774520940227Piantadosi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32666816>
5. **Waste in COVID-19 clinical trials conducted in western Europe.** *Eur J Intern Med* 2020; Dal-Re R, Mahillo-Fernandez I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653152>
6. **Clinical trials in the pandemic age: What is fit for purpose?** *Gates Open Res* 2020; 4:58Hartman D, Heaton P, Cammack N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656501>
7. **QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.** *J. Interv. Card. Electrophysiol.* 2020; B CH, Greige N, J AQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32654098>
8. **Electroencephalogram (EEG) in COVID-19: A systematic retrospective study.** *Neurophysiol. Clin.* 2020; Petrescu AM, Taussig D, Bouilleret V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653111>
9. **The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:646Denholm JT, Davis J, Paterson D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665040>
10. **Breath Regulation and yogic Exercise An online Therapy for calm and Happiness (BREATH) for frontline hospital and long-term care home staff managing the COVID-19 pandemic: A structured summary of a study protocol for a feasibility study for a randomised controlled trial.** *Trials* 2020; 21:648Lai KSP, Watt C, Ionson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665041>
11. **A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:639Smith K, Pace A, Ortiz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660611>
12. **Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada.** *Trials* 2020; 21:647Wright JK, Tan DHS, Walmsley SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32665039>

## Vaccines (11 articles)

1. **Gestational diabetes mellitus testing in the COVID-19 pandemic: The problems with simplifying the diagnostic process.** *Aust N Z J Obstet Gynaecol* 2020; van Gemert TE, Moses RG, Pape AV, Morris GJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662072>
2. **COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.** *Clin. Exp. Immunol.* 2020; Baker D, Roberts CA, Pryce G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671831>
3. **Data mining and analysis of scientific research data records on Covid-19 mortality, immunity, and vaccine development - In the first wave of the Covid-19 pandemic.** *Diabetes Metab Syndr* 2020; 14:1121-1132Radanliev P, De Roure D, Walton R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32659695>
4. **The combination of artificial intelligence and systems biology for intelligent vaccine design.** *Expert Opin Drug Discov* 2020;1-15Russo G, Reche P, Pennisi M, Pappalardo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662677>
5. **Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development.** *Hum Vaccin Immunother* 2020;1-4Cohen SA, Kellogg C, Equils O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678695>
6. **SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.** *Inflamm Res* 2020; Oberemok VV, Laikova KV, Yurchenko KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656668>
7. **Design of a Multi-epitope Vaccine against SARS-CoV-2 using Immunoinformatics approach.** *Int. J. Biol. Macromol.* 2020; Sanami S, Zandi M, Pourhossein B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682041>
8. **Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach.** *J Biomol Struct Dyn* 2020;1-17Samad A, Ahammad F, Nain Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32677533>
9. **Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate.** *Med. Hypotheses* 2020; 143:110084Acharya R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32663741>
10. **Vaccines for COVID-19: The current state of play.** *Paediatr. Respir. Rev.* 2020; Koirala A, Joo YJ, Khatami A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653463>
11. **The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.** *Vaccine* 2020; Kochhar S, Kim D, Excler JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32653276>

## Women – pregnancy (24 articles)

1. **A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19.** *Acta Obstet Gynecol Scand* 2020; D'Souza R, Malhame I, Teshler L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678949>
2. **COVID-19 and Treg/Th17 imbalance: Potential relationship to pregnancy outcomes.** *Am. J. Reprod. Immunol.* 2020:e13304Muyayalo KP, Huang DH, Zhao SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662111>
3. **SARS-CoV2 and pregnancy: an Invisible enemy?** *Am. J. Reprod. Immunol.* 2020:e13308Verma S, Carter EB, Mysorekar IU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32678975>

4. **Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic.** *BMC Med* 2020; 18:220Kyrou I, Karteris E, Robbins T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32664957>
5. **Adaptation of Coronavirus (COVID-19) protocols to a Parisian maternity unit during the 2020 pandemic: a managerial perspective.** *Disaster Med Public Health Prep* 2020:1-10Ghanchi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660662>
6. **Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?** *Elife* 2020; 9Pique-Regi R, Romero R, Tarca AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662421>
7. **Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy?** *ESMO Open* 2020; 5Zambelli A, Tondini CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661020>
8. **Fertility Preservation in Cancer Patients During the Coronavirus (COVID-19) Pandemic.** *Front. Oncol.* 2020; 10:1009Dellino M, Minoia C, Paradiso AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656087>
9. **The COVID-19 Pandemic: Is It A Wolf Consuming Fertility?** *Int J Fertil Steril* 2020; 14:159-160Napolitano L, Barone B, Crocetto F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681630>
10. **Pre-gestational diabetes during the COVID-19 pandemic in Bergamo, Italy.** *Int J Gynaecol Obstet* 2020; Dodesini AR, Galliani S, Ciriello E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32657430>
11. **A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study.** *Int J Gynaecol Obstet* 2020; Sahin D, Tanacan A, Erol SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32682342>
12. **SARS-CoV-2 testing in infertile patients: different recommendations in Europe and America.** *J. Assist. Reprod. Genet.* 2020; La Marca A, Nelson SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681280>
13. **COVID-19 screening during fertility treatment: how do guidelines compare against each other?** *J. Assist. Reprod. Genet.* 2020; Papathanasiou A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32656589>
14. **Addressing male sexual and reproductive health in the wake of COVID-19 outbreak.** *J. Endocrinol. Invest.* 2020; Sansone A, Mollaioli D, Ciocca G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32661947>
15. **SARS-CoV-2 is not present in the vaginal fluid of pregnant women with COVID-19.** *J Matern Fetal Neonatal Med* 2020:1-3Aslan MM, Uslu Yuvaci H, Kose O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32669014>
16. **Personal Protective Equipment during the COVID-19 pandemic and operative time in cesarean section: retrospective cohort study.** *J Matern Fetal Neonatal Med* 2020:1-4Cuerva MJ, Carbonell M, Martin Palumbo G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662314>
17. **SARS-CoV-2 infection testing at delivery: a clinical and epidemiological priority.** *J Matern Fetal Neonatal Med* 2020:1-3Ferrazzi E, Beretta P, Bianchi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660281>
18. **Maternal mortality and COVID-19.** *J Matern Fetal Neonatal Med* 2020:1-7Takemoto MLS, Menezes MO, Andreucci CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32674646>
19. **Universal screening for SARS-CoV-2 before labor admission during Covid-19 pandemic in Madrid.** *J. Perinat. Med.* 2020; Herraiz I, Folgueira D, Villalain C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32681783>
20. **Adverse outcomes in SAR-CoV-2 (COVID-19) and SARS virus related pregnancies with probable vertical transmission.** *JBRA Assist Reprod* 2020; 24:351-357Bahadur G, Homburg R, Yoong W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662955>
21. **Using Prenatal Blood Samples to Evaluate COVID-19 Rapid Serologic Tests Specificity.** *Matern Child Health J* 2020; Alger J, Cafferata ML, Alvarado T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32671537>
22. **[SARS-CoV-2 infection: implications for sexual and reproductive health. A position statement of the Asociacion Espanola de Andrologia, Medicina Sexual y Reproductiva (ASESA)].** *Rev Int Androl* 2020; 18:117-123Jose FG, Gonzalez JGA, Molina JMC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660697>
23. **Health systems recovery from COVID-19: a window of opportunity for (in)fertility care.** *Sex Reprod Health Matters* 2020; 28:1790090Affun-Adegbulu C, Sarkar NDP, Abejirinde IO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32662361>
24. **Lung ultrasound in pregnant women during the COVID-19 pandemic: an interobserver agreement study among obstetricians.** *Ultrasonography* 2020; Yassa M, Mutlu MA, Birol P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32660204>

---

to subscribe click [here](#)

---